TheodoreKarrisonTheodore Karrison41.78927490000000-87.601250000000002356Karrison, Theodore+1 (773) 702-9326Research Professorprns:coAuthorOfcoauthor ofprns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsvivo:phoneNumberphonePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonAuthorship 1000859Authorship 1002363Authorship 1009042Authorship 1002075Authorship 1014224Authorship 99836427944450Kindler HL, Karrison T, Lu C, Gandara DR, Stevenson J, Krug L, Janne P, Guterz TL, Stadler WM, Vokes EEJournal of clinical oncology : official journal of the American Society of Clinical OncologyA multicenter, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM). J Clin Oncol. 2005 Jun; 23(16_suppl):7019.J Clin Oncol2005-06-01T00:00:002005A multicenter, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM).27945465Vokes EE, Cohen EE, Mauer AM, Karrison TG, Wong SJ, Skoog-Sluman LJ, Kozloff MF, Dancey J, Dekker AJournal of clinical oncology : official journal of the American Society of Clinical OncologyA phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). J Clin Oncol. 2005 Jun; 23(16_suppl):5504.J Clin Oncol2005-06-01T00:00:002005A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC).27948963Maitland ML, Kasza KE, Lacouture ME, Liu W, Soltani K, Kozloff MF, Hoffman PC, Salgia R, Karrison T, Vokes EEJournal of clinical oncology : official journal of the American Society of Clinical OncologyRefining epidermal growth factor receptor (EGFR) -inhibition-related rash (EIRR) phenotypes with a cetuximab (C) monotherapy stage of a phase II trial for non-small cell lung cancer (NSCLC). J Clin Oncol. 2008 May 20; 26(15_suppl):8089.J Clin Oncol2008-05-20T00:00:002008Refining epidermal growth factor receptor (EGFR) -inhibition-related rash (EIRR) phenotypes with a cetuximab (C) monotherapy stage of a phase II trial for non-small cell lung cancer (NSCLC).27969530Shah S, Wood K, Brisson R, Karrison T, Hensing T, Luke JJ, Patel JDJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerPS01.63: Clinical Characteristics of Acquired Resistance with Anti-PD-1/PD-L1 in Non-Small Cell Lung Cancer (NSCLC): Topic: Medical Oncology. J Thorac Oncol. 2016 Nov; 11(11S):S310.J Thorac Oncol2016-10-28T00:00:002016PS01.63: Clinical Characteristics of Acquired Resistance with Anti-PD-1/PD-L1 in Non-Small Cell Lung Cancer (NSCLC): Topic: Medical Oncology.27949226Kindler HL, Gangadhar T, Karrison T, Hochster HS, Moore MJ, Micetich K, Sun W, Catenacci DV, Stadler WM, Vokes EEJournal of clinical oncology : official journal of the American Society of Clinical OncologyFinal analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC). J Clin Oncol. 2008 May 20; 26(15_suppl):4502.J Clin Oncol2008-05-20T00:00:002008Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC).27944284Smith SM, Pro B, van Besien K, Conner K, Karrison T, Wong S, Stiff P, Vokes EJournal of clinical oncology : official journal of the American Society of Clinical OncologyA phase II study of Epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin's lymphomas. J Clin Oncol. 2005 Jun; 23(16_suppl):6625.J Clin Oncol2005-06-01T00:00:002005A phase II study of Epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin's lymphomas.Authorship 1029071428419407Galanina N, Smith SM, Liao C, Petrich A, Libao B, Gartenhaus R, Westin JR, Cohen KS, Knost JA, Stadler WM, Doyle A, Karrison T, Gordon LI, Evens AMBritish journal of haematologyUniversity of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL. Br J Haematol. 2018 04; 181(2):264-267.Br J Haematol2017-04-17T00:00:002017University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.D000971Procedures30624340.47627Antineoplastic Combined Chemotherapy ProtocolsAuthorship 1121893Authorship 1167992Authorship 1192042Authorship 12013012Authorship 1207361Authorship 1212236Authorship 1212333Authorship 1232562Authorship 1237931Authorship 125318429327706Rosen LE, Karrison T, Ananthanarayanan V, Gallan AJ, Adusumilli PS, Alchami FS, Attanoos R, Brcic L, Butnor KJ, Galateau-Sallé F, Hiroshima K, Kadota K, Klampatsa A, Stang NL, Lindenmann J, Litzky LA, Marchevsky A, Medeiros F, Montero MA, Moore DA, Nabeshima K, Pavlisko EN, Roggli VL, Sauter JL, Sharma A, Sheaff M, Travis WD, Vigneswaran WT, Vrugt B, Walts AE, Tjota MY, Krausz T, Husain ANModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncNuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. Mod Pathol. 2018 04; 31(4):598-606.Mod Pathol2018-01-12T00:00:002018Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study.29590007Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJJournal of clinical oncology : official journal of the American Society of Clinical OncologyProspective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 2018 05 10; 36(14):1389-1395.J Clin Oncol2018-03-28T00:00:002018Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.29216559Alexander DA, Northcross A, Karrison T, Morhasson-Bello O, Wilson N, Atalabi OM, Dutta A, Adu D, Ibigbami T, Olamijulo J, Adepoju D, Ojengbede O, Olopade COEnvironment internationalPregnancy outcomes and ethanol cook stove intervention: A randomized-controlled trial in Ibadan, Nigeria. Environ Int. 2018 02; 111:152-163.Environ Int2017-12-20T00:00:002017Pregnancy outcomes and ethanol cook stove intervention: A randomized-controlled trial in Ibadan, Nigeria.30086071Karrison TG, Philip Schumm L, Kocherginsky M, Thisted R, Dirschl DR, Rogers SThe journal of trauma and acute care surgeryEffects of driving distance and transport time on mortality among Level I and II traumas occurring in a metropolitan area. J Trauma Acute Care Surg. 2018 Oct; 85(4):756-765.J Trauma Acute Care Surg2018-10-01T00:00:002018Effects of driving distance and transport time on mortality among Level I and II traumas occurring in a metropolitan area.29437535Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJJournal of clinical oncology : official journal of the American Society of Clinical OncologySafety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.J Clin Oncol2018-02-13T00:00:002018Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.30188785Szmulewitz RZ, Karrison T, Stadler WM, Ratain MJJournal of clinical oncology : official journal of the American Society of Clinical OncologyLow-Dose Abiraterone With Food: Rebutting an Editorial. J Clin Oncol. 2018 10 20; 36(30):3060-3061.J Clin Oncol2018-09-06T00:00:002018Low-Dose Abiraterone With Food: Rebutting an Editorial.29948021Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MRCancer chemotherapy and pharmacologyA pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317.Cancer Chemother Pharmacol2018-06-09T00:00:002018A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.29435109Shah S, Wood K, Labadie B, Won B, Brisson R, Karrison T, Hensing T, Kozloff M, Bao R, Patel JD, Luke JJOncotargetClinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer. Oncotarget. 2018 Jan 12; 9(4):4375-4384.Oncotarget2017-12-15T00:00:002017Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer.30481287Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, Gooi Z, Lingen MW, Villaflor VM, Ginat DT, Haraf DJ, Vokes EEAnnals of oncology : official journal of the European Society for Medical OncologyOPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 02 01; 30(2):297-302.Ann Oncol2019-02-01T00:00:002019OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.29502444Karrison T, Kocherginsky MClinical trials (London, England)Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials? Clin Trials. 2018 04; 15(2):178-188.Clin Trials2018-03-04T00:00:002018Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials?Authorship 125833530557212Duma A, Maleczek M, Panjikaran B, Herkner H, Karrison T, Nagele PAnesthesiologyMajor Adverse Cardiac Events and Mortality Associated with Electroconvulsive Therapy: A Systematic Review and Meta-analysis. Anesthesiology. 2019 01; 130(1):83-91.Anesthesiology2019-01-01T00:00:002019Major Adverse Cardiac Events and Mortality Associated with Electroconvulsive Therapy: A Systematic Review and Meta-analysis.Authorship 126708330645764Sharma MR, Joshi SS, Karrison TG, Allen K, Suh G, Marsh R, Kozloff MF, Polite BN, Catenacci DVT, Kindler HLCancerA UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer. 2019 05 15; 125(10):1629-1636.Cancer2019-01-15T00:00:002019A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.Authorship 127066330707764Godfrey JK, Nabhan C, Karrison T, Kline JP, Cohen KS, Bishop MR, Stadler WM, Karmali R, Venugopal P, Rapoport AP, Smith SMCancerPhase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.Cancer2019-02-01T00:00:002019Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.30738034Ollech JE, Aharoni-Golan M, Weisshof R, Normatov I, Sapp AR, Kalakonda A, Israel A, Glick LR, Karrison T, Dalal SR, Sakuraba A, Cohen RD, Rubin DT, Pekow JGastrointestinal endoscopyDifferential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. Gastrointest Endosc. 2019 08; 90(2):269-275.Gastrointest Endosc2019-02-06T00:00:002019Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease.Authorship 1297941631124580Jakubowiak AJ, Jasielec JK, Rosenbaum CA, Cole CE, Chari A, Mikhael J, Nam J, McIver A, Severson E, Stephens LA, Tinari K, Rosebeck S, Zimmerman TM, Hycner T, Turowski A, Karrison T, Zonder JABritish journal of haematologyPhase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol. 2019 08; 186(4):549-560.Br J Haematol2019-05-24T00:00:002019Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.Authorship 129944431168601Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, Gooi Z, Lingen MW, Villaflor VM, Ginat DT, Haraf DJ, Vokes EEAnnals of oncology : official journal of the European Society for Medical OncologyOPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 10 01; 30(10):1673.Ann Oncol2019-10-01T00:00:002019OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.Authorship 130534231274208RamÃrez J, House LK, Karrison TG, Janisch LA, Turcich M, Salgia R, Ratain MJ, Sharma MRJournal of clinical pharmacologyProlonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib. J Clin Pharmacol. 2019 12; 59(12):1632-1640.J Clin Pharmacol2019-07-05T00:00:002019Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib.Authorship 132466831433489Truong TM, Apfelbaum J, Shahul S, Anitescu M, Danahey K, Knoebel RW, Liebovitz D, Karrison T, van Wijk XMR, Yeo KJ, Meltzer D, Ratain MJ, O'Donnell PHClinical pharmacology and therapeuticsThe ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care. Clin Pharmacol Ther. 2019 12; 106(6):1179-1183.Clin Pharmacol Ther2019-08-21T00:00:002019The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care.Authorship 1327201131491752McLone D, Frim D, Penn R, Swisher CN, Heydemann P, Boyer KM, Noble AG, Rabiah PK, Withers S, Wroblewski K, Karrison T, Hutson S, Wheeler K, Cohen W, Lykins J, McLeod RJournal of neurosurgery. PediatricsOutcomes of hydrocephalus secondary to congenital toxoplasmosis. J Neurosurg Pediatr. 2019 Sep 06; 1-8.J Neurosurg Pediatr2019-09-06T00:00:002019Outcomes of hydrocephalus secondary to congenital toxoplasmosis.Authorship 133134331558477Joshi SS, Catenacci DVT, Karrison TG, Peterson JD, Zalupski MM, Sehdev A, Wade J, Sadiq A, Picozzi VJ, Amico A, Marsh R, Kozloff MF, Polite BN, Kindler HL, Sharma MRClinical cancer research : an official journal of the American Association for Cancer ResearchClinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing. Clin Cancer Res. 2020 01 01; 26(1):18-24.Clin Cancer Res2019-09-26T00:00:002019Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing.Authorship 133712931639754Leung EKY, Lee CC, Angelos P, Kaplan EL, Grogan RH, Sarracino DA, Krastins B, Lopez MF, Karrison T, Yeo KJThe journal of applied laboratory medicineAnalytical Differences in Intraoperative Parathyroid Hormone Assays. J Appl Lab Med. 2019 03; 3(5):788-798.J Appl Lab Med2019-02-01T00:00:002019Analytical Differences in Intraoperative Parathyroid Hormone Assays.Authorship 134735231831634Schreiber K, Karrison TG, Wolf SP, Kiyotani K, Steiner M, Littmann ER, Pamer EG, Kammertoens T, Schreiber H, Leisegang MCancer immunology researchImpact of TCR Diversity on the Development of Transplanted or Chemically Induced Tumors. Cancer Immunol Res. 2020 02; 8(2):192-202.Cancer Immunol Res2019-12-12T00:00:002019Impact of TCR Diversity on the Development of Transplanted or Chemically Induced Tumors.Authorship 135762432058557Catenacci DVT, Chase L, Lomnicki S, Karrison T, de Wilton Marsh R, Rampurwala MM, Narula S, Alpert L, Setia N, Xiao SY, Hart J, Siddiqui UD, Peterson B, Moore K, Kipping-Johnson K, Markevicius U, Gordon B, Allen K, Racette C, Maron SB, Liao CY, Polite BN, Kindler HL, Turaga K, Prachand VN, Roggin KK, Ferguson MK, Posner MCJAMA network openEvaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290.JAMA Netw Open2020-02-05T00:00:002020Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial.Authorship 1359378Authorship 135943332074275Cahill KE, Karimi YH, Karrison TG, Jain N, Green M, Weiner H, Fulton N, Kadri S, Godley LA, Artz AS, Liu H, Thirman MJ, Le Beau MM, McNerney ME, Segal J, Larson RA, Stock W, Odenike OBlood advancesA phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Adv. 2020 02 25; 4(4):599-606.Blood Adv2020-02-25T00:00:002020A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia.32073648Kochanny SE, Worden FP, Adkins DR, Lim DW, Bauman JE, Wagner SA, Brisson RJ, Karrison TG, Stadler WM, Vokes EE, Seiwert TYCancerA randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Cancer. 2020 05 15; 126(10):2146-2152.Cancer2020-02-19T00:00:002020A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.Authorship 1360529Authorship 1365361132221533Böttinger P, Schreiber K, Hyjek E, Krausz T, Spiotto MT, Steiner M, Idel C, Booras H, Beck-Engeser G, Riederer J, Willimsky G, Wolf SP, Karrison T, Jensen E, Weichselbaum RR, Nakamura Y, Yew PY, Lambert PF, Kurita T, Kiyotani K, Leisegang M, Schreiber HCarcinogenesisCooperation of genes in HPV16 E6/E7-dependent cervicovaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens. Carcinogenesis. 2020 11 13; 41(11):1605-1615.Carcinogenesis2020-11-13T00:00:002020Cooperation of genes in HPV16 E6/E7-dependent cervicovaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens.Authorship 1372661032365226Seiwert TY, Kochanny S, Wood K, Worden FP, Adkins D, Wade JL, Sleckman BG, Anderson D, Brisson RJ, Karrison T, Stadler WM, Vokes EECancerA randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. Cancer. 2020 07 15; 126(14):3237-3243.Cancer2020-05-04T00:00:002020A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.32628583Ntekim AI, Ibraheem A, Sofoluwe AA, Kotila O, Babalola C, Karrison T, Olopade COJCO global oncologyARETTA: Assessing Response to Neoadjuvant Taxotere and Subcutaneous Trastuzumab in Nigerian Women With HER2-Positive Breast Cancer: A Study Protocol. JCO Glob Oncol. 2020 07; 6:983-990.JCO Glob Oncol2020-07-01T00:00:002020ARETTA: Assessing Response to Neoadjuvant Taxotere and Subcutaneous Trastuzumab in Nigerian Women With HER2-Positive Breast Cancer: A Study Protocol.Authorship 1397211432743594Strohbehn GW, Heiss BL, Rouhani SJ, Trujillo JA, Yu J, Kacew AJ, Higgs EF, Bloodworth JC, Cabanov A, Wright RC, Koziol A, Weiss A, Danahey K, Karrison TG, Edens CC, Ventura IB, Pettit NN, Patel B, Pisano J, Strek ME, Gajewski TF, Ratain MJ, Reid PDmedRxiv : the preprint server for health sciencesCOVIDOSE: Low-dose tocilizumab in the treatment of Covid-19. medRxiv. 2020 Jul 26.medRxiv2020-07-26T00:00:002020COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19.8420886Vijayakumar S, Awan A, Karrison T, Culbert H, Chan S, Kolker J, Low N, Halpern H, Rubin S, Chen GTInternational journal of radiation oncology, biology, physicsAcute toxicity during external-beam radiotherapy for localized prostate cancer: comparison of different techniques. Int J Radiat Oncol Biol Phys. 1993 Jan 15; 25(2):359-71.Int J Radiat Oncol Biol Phys1993-01-15T00:00:001993Acute toxicity during external-beam radiotherapy for localized prostate cancer: comparison of different techniques.1376933Vijayakumar S, Quadri SF, Karrison TG, Trinidad CO, Chan SK, Halpern HJ, Rubin SJ, Sutton HGRadiologyLocalized prostate cancer: use of serial prostate-specific antigen measurements during radiation therapy. Radiology. 1992 Jul; 184(1):271-4.Radiology1992-07-01T00:00:001992Localized prostate cancer: use of serial prostate-specific antigen measurements during radiation therapy.Authorship 141377433028595Luke JJ, Onderdonk BE, Bhave SR, Karrison T, Lemons JM, Chang P, Zha Y, Carll T, Krausz T, Huang L, Martinez C, Janisch LA, Hseu RD, Moroney JW, Patel JD, Khodarev NN, Salama JK, Ott PA, Fleming GF, Gajewski TF, Weichselbaum RR, Pitroda SP, Chmura SJClinical cancer research : an official journal of the American Association for Cancer ResearchImproved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.Clin Cancer Res2020-10-07T00:00:002020Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial.8976223Goldfischer ER, Cromie WJ, Karrison TG, Naszkiewicz L, Gerber GSThe Journal of urologyRandomized, prospective, double-blind study of the effects on pain perception of lidocaine jelly versus plain lubricant during outpatient rigid cystoscopy. J Urol. 1997 Jan; 157(1):90-4.J Urol1997-01-01T00:00:001997Randomized, prospective, double-blind study of the effects on pain perception of lidocaine jelly versus plain lubricant during outpatient rigid cystoscopy.1465284Vokes EE, Beckett M, Karrison T, Weichselbaum RROncologyThe interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines. Oncology. 1992; 49(6):454-60.Oncology1992-01-01T00:00:001992The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines.10533006Chin MH, Jin L, Karrison TG, Mulliken R, Hayley DC, Walter J, Miller A, Friedmann PDAnnals of emergency medicineOlder patients' health-related quality of life around an episode of emergency illness. Ann Emerg Med. 1999 Nov; 34(5):595-603.Ann Emerg Med1999-11-01T00:00:001999Older patients' health-related quality of life around an episode of emergency illness.9542481Yuan CS, Karrison T, Wu JA, Lowell TK, Lynch JP, Foss JFClinical pharmacology and therapeuticsDose-related effects of oral acetaminophen on cold-induced pain: a double-blind, randomized, placebo-controlled trial. Clin Pharmacol Ther. 1998 Mar; 63(3):379-83.Clin Pharmacol Ther1998-03-01T00:00:001998Dose-related effects of oral acetaminophen on cold-induced pain: a double-blind, randomized, placebo-controlled trial.10694601Ferguson MK, Karrison TThe Journal of thoracic and cardiovascular surgeryDoes pneumonectomy for lung cancer adversely influence long-term survival? J Thorac Cardiovasc Surg. 2000 Mar; 119(3):440-8.J Thorac Cardiovasc Surg2000-03-01T00:00:002000Does pneumonectomy for lung cancer adversely influence long-term survival?9314627McNabb W, Quinn M, Kerver J, Cook S, Karrison TDiabetes careThe PATHWAYS church-based weight loss program for urban African-American women at risk for diabetes. Diabetes Care. 1997 Oct; 20(10):1518-23.Diabetes Care1997-10-01T00:00:001997The PATHWAYS church-based weight loss program for urban African-American women at risk for diabetes.10609925Chin MH, Wang LC, Jin L, Mulliken R, Walter J, Hayley DC, Karrison TG, Nerney MP, Miller A, Friedmann PDAcademic emergency medicine : official journal of the Society for Academic Emergency MedicineAppropriateness of medication selection for older persons in an urban academic emergency department. Acad Emerg Med. 1999 Dec; 6(12):1232-42.Acad Emerg Med1999-12-01T00:00:001999Appropriateness of medication selection for older persons in an urban academic emergency department.10705866Chin MH, Auerbach SB, Cook S, Harrison JF, Koppert J, Jin L, Thiel F, Karrison TG, Harrand AG, Schaefer CT, Takashima HT, Egbert N, Chiu SC, McNabb WLAmerican journal of public healthQuality of diabetes care in community health centers. Am J Public Health. 2000 Mar; 90(3):431-4.Am J Public Health2000-03-01T00:00:002000Quality of diabetes care in community health centers.9558278Gokhale R, Favus MJ, Karrison T, Sutton MM, Rich B, Kirschner BSGastroenterologyBone mineral density assessment in children with inflammatory bowel disease. Gastroenterology. 1998 May; 114(5):902-11.Gastroenterology1998-05-01T00:00:001998Bone mineral density assessment in children with inflammatory bowel disease.11239256Friedmann PD, Jin L, Karrison TG, Hayley DC, Mulliken R, Walter J, Chin MHThe American journal of emergency medicineEarly revisit, hospitalization, or death among older persons discharged from the ED. Am J Emerg Med. 2001 Mar; 19(2):125-9.Am J Emerg Med2001-03-01T00:00:002001Early revisit, hospitalization, or death among older persons discharged from the ED.11193231Draganich LF, Zacny J, Klafta J, Karrison TThe journals of gerontology. Series A, Biological sciences and medical sciencesThe effects of antidepressants on obstructed and unobstructed gait in healthy elderly people. J Gerontol A Biol Sci Med Sci. 2001 Jan; 56(1):M36-41.J Gerontol A Biol Sci Med Sci2001-01-01T00:00:002001The effects of antidepressants on obstructed and unobstructed gait in healthy elderly people.10437864Ober C, Karrison T, Odem RR, Barnes RB, Branch DW, Stephenson MD, Baron B, Walker MA, Scott JR, Schreiber JRLancet (London, England)Mononuclear-cell immunisation in prevention of recurrent miscarriages: a randomised trial. Lancet. 1999 Jul 31; 354(9176):365-9.Lancet1999-07-31T00:00:001999Mononuclear-cell immunisation in prevention of recurrent miscarriages: a randomised trial.1587414Tripathi RC, Kirschner BS, Kipp M, Tripathi BJ, Slotwiner D, Borisuth NS, Karrison T, Ernest JTGastroenterologyCorticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure. Gastroenterology. 1992 Jun; 102(6):1957-61.Gastroenterology1992-06-01T00:00:001992Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure.10801249Yuan CS, Foss JF, O'Connor M, Karrison T, Osinski J, Roizen MF, Moss JClinical pharmacology and therapeuticsEffects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin Pharmacol Ther. 2000 Apr; 67(4):398-404.Clin Pharmacol Ther2000-04-01T00:00:002000Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time.9370176Haas M, Meehan SM, Karrison TG, Spargo BHAmerican journal of kidney diseases : the official journal of the National Kidney FoundationChanging etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis. 1997 Nov; 30(5):621-31.Am J Kidney Dis1997-11-01T00:00:001997Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997.9881742Tsai AF, Kaufman KA, Walker MA, Karrison TG, Odem RR, Barnes RB, Scott JR, Schreiber JR, Stephenson MD, Ober CJournal of reproductive immunologyTransmission disequilibrium of maternally-inherited CTLA-4 microsatellite alleles in idiopathic recurrent miscarriage. J Reprod Immunol. 1998 Nov; 40(2):147-57.J Reprod Immunol1998-11-01T00:00:001998Transmission disequilibrium of maternally-inherited CTLA-4 microsatellite alleles in idiopathic recurrent miscarriage.D016032Concepts & IdeasProcedures2778500.730148Randomized Controlled Trials as Topic10473013Friedmann PD, Jin L, Karrison T, Nerney M, Hayley DC, Mulliken R, Walter J, Miller A, Chin MHThe American journal of drug and alcohol abuseThe effect of alcohol abuse on the health status of older adults seen in the emergency department. Am J Drug Alcohol Abuse. 1999 Aug; 25(3):529-42.Am J Drug Alcohol Abuse1999-08-01T00:00:001999The effect of alcohol abuse on the health status of older adults seen in the emergency department.11752106Yuan CS, Wei G, Foss JF, O'Connor M, Karrison T, Osinski JThe Journal of pharmacology and experimental therapeuticsEffects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther. 2002 Jan; 300(1):118-23.J Pharmacol Exp Ther2002-01-01T00:00:002002Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial.10647800Yuan CS, Foss JF, O'Connor M, Osinski J, Karrison T, Moss J, Roizen MFJAMAMethylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA. 2000 Jan 19; 283(3):367-72.JAMA2000-01-19T00:00:002000Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial.33234578Catenacci DVT, Moya S, Lomnicki S, Chase LM, Peterson BF, Reizine N, Alpert L, Setia N, Xiao SY, Hart J, Siddiqui UD, Hogarth DK, Eng OS, Turaga K, Roggin K, Posner MC, Chang P, Narula S, Rampurwala M, Ji Y, Karrison T, Liao CY, Polite BN, Kindler HLCancer discoveryPersonalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325.Cancer Discov2020-11-24T00:00:002020Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease.11990381Iyer L, Das S, Janisch L, Wen M, RamÃrez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJThe pharmacogenomics journalUGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002; 2(1):43-7.Pharmacogenomics J2002-01-01T00:00:002002UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.12082466Herschel M, Karrison T, Wen M, Caldarelli L, Baron BJournal of perinatology : official journal of the California Perinatal AssociationEvaluation of the direct antiglobulin (Coombs') test for identifying newborns at risk for hemolysis as determined by end-tidal carbon monoxide concentration (ETCOc); and comparison of the Coombs' test with ETCOc for detecting significant jaundice. J Perinatol. 2002 Jul-Aug; 22(5):341-7.J Perinatol2002-07-01T00:00:002002Evaluation of the direct antiglobulin (Coombs') test for identifying newborns at risk for hemolysis as determined by end-tidal carbon monoxide concentration (ETCOc); and comparison of the Coombs' test with ETCOc for detecting significant jaundice.Authorship 14206814Authorship 14220821Authorship 1422221133238820Mansour A, Loggini A, Goldenberg FD, Kramer C, Naidech AM, Ammar FE, Vasenina V, Castro B, Das P, Horowitz PM, Karrison T, Zakrison T, Hampton D, Rogers SO, Lazaridis CJournal of neurotraumaCoagulopathy as a Surrogate of Severity of Injury in Penetrating Brain Injury. J Neurotrauma. 2021 Jun 01; 38(13):1821-1826.J Neurotrauma2021-01-20T00:00:002021Coagulopathy as a Surrogate of Severity of Injury in Penetrating Brain Injury.33210302Strohbehn GW, Heiss BL, Rouhani SJ, Trujillo JA, Yu J, Kacew AJ, Higgs EF, Bloodworth JC, Cabanov A, Wright RC, Koziol AK, Weiss A, Danahey K, Karrison TG, Edens CC, Bauer Ventura I, Pettit NN, Patel BK, Pisano J, Strek ME, Gajewski TF, Ratain MJ, Reid PDClinical pharmacology and therapeuticsCOVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther. 2021 03; 109(3):688-696.Clin Pharmacol Ther2020-12-10T00:00:002020COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.12093957Herschel M, Karrison T, Wen M, Caldarelli L, Baron BPediatricsIsoimmunization is unlikely to be the cause of hemolysis in ABO-incompatible but direct antiglobulin test-negative neonates. Pediatrics. 2002 Jul; 110(1 Pt 1):127-30.Pediatrics2002-07-01T00:00:002002Isoimmunization is unlikely to be the cause of hemolysis in ABO-incompatible but direct antiglobulin test-negative neonates.10943525McLeod R, Boyer K, Roizen N, Stein L, Swisher C, Holfels E, Hopkins J, Mack D, Karrison T, Patel D, Pfiffner L, Remington J, Withers S, Meyers S, Aitchison V, Mets M, Rabiah P, Meier PCurrent clinical topics in infectious diseasesThe child with congenital toxoplasmosis. Curr Clin Top Infect Dis. 2000; 20:189-208.Curr Clin Top Infect Dis2000-01-01T00:00:002000The child with congenital toxoplasmosis.11051254Poelman SM, Adeyanju MO, Robertson MA, Recant WM, Karrison T, Fleming GF, Olopade OI, Conzen SDClinical cancer research : an official journal of the American Association for Cancer ResearchHuman breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression. Clin Cancer Res. 2000 Oct; 6(10):4043-8.Clin Cancer Res2000-10-01T00:00:002000Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression.11306453Kim HL, Vander Griend DJ, Yang X, Benson DA, Dubauskas Z, Yoshida BA, Chekmareva MA, Ichikawa Y, Sokoloff MH, Zhan P, Karrison T, Lin A, Stadler WM, Ichikawa T, Rubin MA, Rinker-Schaeffer CWCancer researchMitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res. 2001 Apr 01; 61(7):2833-7.Cancer Res2001-04-01T00:00:002001Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers.12149312Karrison T, Ratain MJournal of clinical oncology : official journal of the American Society of Clinical OncologyTroxacitabine in patients with refractory leukemia. J Clin Oncol. 2002 Aug 01; 20(15):3356; author reply 3356-7.J Clin Oncol2002-08-01T00:00:002002Troxacitabine in patients with refractory leukemia.12171878Dolan ME, Posner M, Karrison T, Radosta J, Steinberg G, Bertucci D, Vujasin L, Ratain MJClinical cancer research : an official journal of the American Association for Cancer ResearchDetermination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors. Clin Cancer Res. 2002 Aug; 8(8):2519-23.Clin Cancer Res2002-08-01T00:00:002002Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors.12511315Shah MN, Glushak C, Karrison TG, Mulliken R, Walter J, Friedmann PD, Hayley DC, Chin MHAcademic emergency medicine : official journal of the Society for Academic Emergency MedicinePredictors of emergency medical services utilization by elders. Acad Emerg Med. 2003 Jan; 10(1):52-8.Acad Emerg Med2003-01-01T00:00:002003Predictors of emergency medical services utilization by elders.11468608Nerney MP, Chin MH, Jin L, Karrison TG, Walter J, Mulliken R, Miller A, Hayley DC, Friedmann PDAnnals of emergency medicineFactors associated with older patients' satisfaction with care in an inner-city emergency department. Ann Emerg Med. 2001 Aug; 38(2):140-5.Ann Emerg Med2001-08-01T00:00:002001Factors associated with older patients' satisfaction with care in an inner-city emergency department.1892144Elliott WJ, Karrison TThe American journal of medicineIncreased all-cause and cardiac morbidity and mortality associated with the diagonal earlobe crease: a prospective cohort study. Am J Med. 1991 Sep; 91(3):247-54.Am J Med1991-09-01T00:00:001991Increased all-cause and cardiac morbidity and mortality associated with the diagonal earlobe crease: a prospective cohort study.11921270Karrison T, Archer KJ, Espinosa R, Wen M, Huo DGenes, chromosomes & cancerData management and statistical methods used in the analysis of balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and therapy-related acute leukemia: report from an international workshop. Genes Chromosomes Cancer. 2002 Apr; 33(4):346-61.Genes Chromosomes Cancer2002-04-01T00:00:002002Data management and statistical methods used in the analysis of balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and therapy-related acute leukemia: report from an international workshop.14567598Macdonald RL, Rosengart A, Huo D, Karrison TJournal of neurosurgeryFactors associated with the development of vasospasm after planned surgical treatment of aneurysmal subarachnoid hemorrhage. J Neurosurg. 2003 Oct; 99(4):644-52.J Neurosurg2003-10-01T00:00:002003Factors associated with the development of vasospasm after planned surgical treatment of aneurysmal subarachnoid hemorrhage.12438272Yamada SD, Hickson JA, Hrobowski Y, Vander Griend DJ, Benson D, Montag A, Karrison T, Huo D, Rutgers J, Adams S, Rinker-Schaeffer CWCancer researchMitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res. 2002 Nov 15; 62(22):6717-23.Cancer Res2002-11-15T00:00:002002Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma.14500050Karrison TG, Huo D, Chappell RControlled clinical trialsA group sequential, response-adaptive design for randomized clinical trials. Control Clin Trials. 2003 Oct; 24(5):506-22.Control Clin Trials2003-10-01T00:00:002003A group sequential, response-adaptive design for randomized clinical trials.14501711Stadler WM, Huo D, George C, Yang X, Ryan CW, Karrison T, Zimmerman TM, Vogelzang NJThe Journal of urologyPrognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol. 2003 Oct; 170(4 Pt 1):1141-5.J Urol2003-10-01T00:00:002003Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer.15161690Stadler WM, Cao D, Vogelzang NJ, Ryan CW, Hoving K, Wright R, Karrison T, Vokes EEClinical cancer research : an official journal of the American Association for Cancer ResearchA randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res. 2004 May 15; 10(10):3365-70.Clin Cancer Res2004-05-15T00:00:002004A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.15723259Fishel ML, Gamcsik MP, Delaney SM, Zuhowski EG, Maher VM, Karrison T, Moschel RC, Egorin MJ, Dolan MECancer chemotherapy and pharmacologyRole of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine. Cancer Chemother Pharmacol. 2005 Apr; 55(4):333-342.Cancer Chemother Pharmacol2004-10-02T00:00:002004Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine.15007088Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, RamÃrez J, Rudin CM, Vokes EE, Ratain MJJournal of clinical oncology : official journal of the American Society of Clinical OncologyGenetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004 Apr 15; 22(8):1382-8.J Clin Oncol2004-03-08T00:00:002004Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.15077191Schreiber K, Cannon RE, Karrison T, Beck-Engeser G, Huo D, Tennant RW, Jensen H, Kast WM, Krausz T, Meredith SC, Chen L, Schreiber HOncogeneStrong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors. Oncogene. 2004 May 13; 23(22):3972-9.Oncogene2004-05-13T00:00:002004Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors.15304465Anselmo J, Cao D, Karrison T, Weiss RE, Refetoff SJAMAFetal loss associated with excess thyroid hormone exposure. JAMA. 2004 Aug 11; 292(6):691-5.JAMA2004-08-11T00:00:002004Fetal loss associated with excess thyroid hormone exposure.12623843Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, Vardiman JW, Rowley JD, Larson RABloodClinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003 Jul 01; 102(1):43-52.Blood2003-03-06T00:00:002003Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.15833844Kimchi ET, Posner MC, Park JO, Darga TE, Kocherginsky M, Karrison T, Hart J, Smith KD, Mezhir JJ, Weichselbaum RR, Khodarev NNCancer researchProgression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res. 2005 Apr 15; 65(8):3146-54.Cancer Res2005-04-15T00:00:002005Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.15831777Yuan CS, Doshan H, Charney MR, O'connor M, Karrison T, Maleckar SA, Israel RJ, Moss JJournal of clinical pharmacologyTolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol. 2005 May; 45(5):538-46.J Clin Pharmacol2005-05-01T00:00:002005Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans.14501509Michelassi F, Lee J, Rubin M, Fichera A, Kasza K, Karrison T, Hurst RDAnnals of surgeryLong-term functional results after ileal pouch anal restorative proctocolectomy for ulcerative colitis: a prospective observational study. Ann Surg. 2003 Sep; 238(3):433-41; discussion 442-5.Ann Surg2003-09-01T00:00:002003Long-term functional results after ileal pouch anal restorative proctocolectomy for ulcerative colitis: a prospective observational study.15375218Baron BW, Anastasi J, Montag A, Huo D, Baron RM, Karrison T, Thirman MJ, Subudhi SK, Chin RK, Felsher DW, Fu YX, McKeithan TW, Baron JMProceedings of the National Academy of Sciences of the United States of AmericaThe human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci U S A. 2004 Sep 28; 101(39):14198-203.Proc Natl Acad Sci U S A2004-09-16T00:00:002004The human BCL6 transgene promotes the development of lymphomas in the mouse.16864640Roizen N, Kasza K, Karrison T, Mets M, Noble AG, Boyer K, Swisher C, Meier P, Remington J, Jalbrzikowski J, McLeod R, Kipp M, Rabiah P, Chamot D, Estes R, Cezar S, Mack D, Pfiffner L, Stein M, Danis B, Patel D, Hopkins J, Holfels E, Stein L, Withers S, Cameron A, Perkins J, Heydemann PPediatricsImpact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies. Pediatrics. 2006 Aug; 118(2):e379-90.Pediatrics2006-07-24T00:00:002006Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies.Medicine-Hematology and Oncology17597499Wicks SM, Tong R, Wang CZ, O'Connor M, Karrison T, Li S, Moss J, Yuan CSThe American journal of Chinese medicineSafety and tolerability of Ganoderma lucidum in healthy subjects: a double-blind randomized placebo-controlled trial. Am J Chin Med. 2007; 35(3):407-14.Am J Chin Med2007-01-01T00:00:002007Safety and tolerability of Ganoderma lucidum in healthy subjects: a double-blind randomized placebo-controlled trial.2026031Hall JB, White SR, Karrison TCritical care medicineEfficacy of daily routine chest radiographs in intubated, mechanically ventilated patients. Crit Care Med. 1991 May; 19(5):689-93.Crit Care Med1991-05-01T00:00:001991Efficacy of daily routine chest radiographs in intubated, mechanically ventilated patients.16619149McLeod R, Boyer K, Karrison T, Kasza K, Swisher C, Roizen N, Jalbrzikowski J, Remington J, Heydemann P, Noble AG, Mets M, Holfels E, Withers S, Latkany P, Meier P, Toxoplasmosis Study GroupClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaOutcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin Infect Dis. 2006 May 15; 42(10):1383-94.Clin Infect Dis2006-04-11T00:00:002006Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study.16760642Argiris A, Cohen E, Karrison T, Esparaz B, Mauer A, Ansari R, Wong S, Lu Y, Pins M, Dancey J, Vokes ECancer biology & therapyA phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther. 2006 Jul; 5(7):766-70.Cancer Biol Ther2006-07-02T00:00:002006A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.15238367Yuan CS, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S, Kasza K, Ang-Lee M, Moss JAnnals of internal medicineBrief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled Trial. Ann Intern Med. 2004 Jul 06; 141(1):23-7.Ann Intern Med2004-07-06T00:00:002004Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled Trial.14996737Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SDCancer researchMicroarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res. 2004 Mar 01; 64(5):1757-64.Cancer Res2004-03-01T00:00:002004Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells.16418266Lee S, Chen J, Zhou G, Shi RZ, Bouffard GG, Kocherginsky M, Ge X, Sun M, Jayathilaka N, Kim YC, Emmanuel N, Bohlander SK, Minden M, Kline J, Ozer O, Larson RA, LeBeau MM, Green ED, Trent J, Karrison T, Liu PP, Wang SM, Rowley JDProceedings of the National Academy of Sciences of the United States of AmericaGene expression profiles in acute myeloid leukemia with common translocations using SAGE. Proc Natl Acad Sci U S A. 2006 Jan 24; 103(4):1030-5.Proc Natl Acad Sci U S A2006-01-17T00:00:002006Gene expression profiles in acute myeloid leukemia with common translocations using SAGE.16838099Vokes TJ, Giger ML, Chinander MR, Karrison TG, Favus MJ, Dixon LBOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USARadiographic texture analysis of densitometer-generated calcaneus images differentiates postmenopausal women with and without fractures. Osteoporos Int. 2006 Oct; 17(10):1472-82.Osteoporos Int2006-07-13T00:00:002006Radiographic texture analysis of densitometer-generated calcaneus images differentiates postmenopausal women with and without fractures.17210514Singh ZN, Huo D, Anastasi J, Smith SM, Karrison T, Le Beau MM, Larson RA, Vardiman JWAmerican journal of clinical pathologyTherapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol. 2007 Feb; 127(2):197-205.Am J Clin Pathol2007-02-01T00:00:002007Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant.17825602Lingen MW, Kalmar JR, Karrison T, Speight PMOral oncologyCritical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol. 2008 Jan; 44(1):10-22.Oral Oncol2007-09-06T00:00:002007Critical evaluation of diagnostic aids for the detection of oral cancer.18297531Gordon MK, Sher D, Karrison T, Kebriaei P, Chuang K, Zhang Y, McDonnell D, Artz A, Godley L, Odenike O, Rich E, Michaelis L, Thirman MJ, Wickrema A, van Besien K, Larson RA, Stock WLeukemia & lymphomaSuccessful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma. 2008 Mar; 49(3):531-7.Leuk Lymphoma2008-03-01T00:00:002008Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.15122080Kindler HL, Avadhani A, Wade-Oliver K, Karrison T, Mani S, Vokes EEInvestigational new drugs9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium. Invest New Drugs. 2004 Aug; 22(3):323-7.Invest New Drugs2004-08-01T00:00:0020049-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium.18309947Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L, Das S, Ramirez J, Poonkuzhali B, Schuetz E, Fackenthal DL, Chen P, Armstrong DK, Brahmer JR, Fleming GF, Vokes EE, Carducci MA, Ratain MJJournal of clinical oncology : official journal of the American Society of Clinical OncologyPharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 01; 26(7):1119-27.J Clin Oncol2008-03-01T00:00:002008Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.14692025Vogelzang NJ, Karrison T, Stadler WM, Garcia J, Cohn H, Kugler J, Troeger T, Giannone L, Arrieta R, Ratain MJ, Vokes EECancerA Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Cancer. 2004 Jan 01; 100(1):65-71.Cancer2004-01-01T00:00:002004A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.17895472Karrison TG, Maitland ML, Stadler WM, Ratain MJJournal of the National Cancer InstituteDesign of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst. 2007 Oct 03; 99(19):1455-61.J Natl Cancer Inst2007-09-25T00:00:002007Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.18760930Ferguson MK, Siddique J, Karrison TEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic SurgeryModeling major lung resection outcomes using classification trees and multiple imputation techniques. Eur J Cardiothorac Surg. 2008 Nov; 34(5):1085-9.Eur J Cardiothorac Surg2008-08-29T00:00:002008Modeling major lung resection outcomes using classification trees and multiple imputation techniques.19228743Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L, Loewy JW, Kindler H, Stadler WM, Knowles HL, Bedrosian C, Ratain MJClinical cancer research : an official journal of the American Association for Cancer ResearchA phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009 Feb 15; 15(4):1428-34.Clin Cancer Res2009-02-15T00:00:002009A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies.18824708Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, Manchen E, Mitchell M, Ratain MJ, Stadler WMJournal of clinical oncology : official journal of the American Society of Clinical OncologyDynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.J Clin Oncol2008-10-01T00:00:002008Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.2494444Schwartz JL, Karrison T, Le Beau MM, Larson RA, Sagher D, Strauss B, Rowley JD, Weichselbaum RRMutation researchChromosomal sensitivity of lymphocytes from individuals with therapy-related acute nonlymphocytic leukemia. Mutat Res. 1989 Apr; 216(2):119-26.Mutat Res1989-04-01T00:00:001989Chromosomal sensitivity of lymphocytes from individuals with therapy-related acute nonlymphocytic leukemia.19282098Szmulewitz R, Mohile S, Posadas E, Kunnavakkam R, Karrison T, Manchen E, Stadler WMEuropean urologyA randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol. 2009 Jul; 56(1):97-103.Eur Urol2009-02-27T00:00:002009A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer.19746591Hollingsworth KL, Zimmerman TM, Karrison T, Oliver A, Williams SFCytotherapyThe CD34+ cell concentration in peripheral blood predicts CD34+ cell yield in the leukapheresis product. Cytotherapy. 1999; 1(2):141-6.Cytotherapy1999-01-01T00:00:001999The CD34+ cell concentration in peripheral blood predicts CD34+ cell yield in the leukapheresis product.D017322Activities & BehaviorsProcedures661730.916828Clinical Trials, Phase II as Topic16514482Peterson AC, Harlin H, Karrison T, Vogelzang NJ, Knost JA, Kugler JW, Lester E, Vokes E, Gajewski TF, Stadler WM, University of Chicago Phase II ConsortiumInvestigational new drugsA randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Invest New Drugs. 2006 Mar; 24(2):141-9.Invest New Drugs2006-03-01T00:00:002006A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.19201650Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A, Vokes EEThe Lancet. OncologyErlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009 Mar; 10(3):247-57.Lancet Oncol2009-02-07T00:00:002009Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.16258101Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM, Vokes EEJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005 Nov 01; 23(31):8033-40.J Clin Oncol2005-11-01T00:00:002005Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.19773379Maitland ML, Kasza KE, Karrison T, Moshier K, Sit L, Black HR, Undevia SD, Stadler WM, Elliott WJ, Ratain MJClinical cancer research : an official journal of the American Association for Cancer ResearchAmbulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009 Oct 01; 15(19):6250-7.Clin Cancer Res2009-09-22T00:00:002009Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.Authorship 146011833882144Onderdonk BE, Dorn PL, Martinez C, Arif F, Cloutier D, Antic T, Golden DW, Karrison T, Pitroda SP, Szmulewitz RZ, Liauw SLCancerA prospective clinical and transcriptomic feasibility study of oral-only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity. Cancer. 2021 08 01; 127(15):2631-2640.Cancer2021-04-21T00:00:002021A prospective clinical and transcriptomic feasibility study of oral-only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity.20421534Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SLJournal of clinical oncology : official journal of the American Society of Clinical OncologyStatin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol. 2010 Jun 01; 28(16):2653-9.J Clin Oncol2010-04-26T00:00:002010Statin use and risk of prostate cancer recurrence in men treated with radiation therapy.20126411Tan YH, Krishnaswamy S, Nandi S, Kanteti R, Vora S, Onel K, Hasina R, Lo FY, El-Hashani E, Cervantes G, Robinson M, Hsu HS, Kales SC, Lipkowitz S, Karrison T, Sattler M, Vokes EE, Wang YC, Salgia RPloS oneCBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One. 2010 Jan 29; 5(1):e8972.PLoS One2010-01-29T00:00:002010CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.17289865Ratain MJ, Karrison TGClinical cancer research : an official journal of the American Association for Cancer ResearchTesting the wrong hypothesis in phase II oncology trials: there is a better alternative. Clin Cancer Res. 2007 Feb 01; 13(3):781-2.Clin Cancer Res2007-02-01T00:00:002007Testing the wrong hypothesis in phase II oncology trials: there is a better alternative.17457044Posadas EM, Undevia S, Manchen E, Wade JL, Colevas AD, Karrison T, Vokes EE, Stadler WMCancer biology & therapyA phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma. Cancer Biol Ther. 2007 Apr; 6(4):490-3.Cancer Biol Ther2007-04-01T00:00:002007A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma.Authorship 1463031633945288Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, Bajaj M, Babu S, Hallmeyer S, Velasco M, Lutzky J, Higgs E, Bao R, Carll TC, Labadie B, Krausz T, Zha Y, Karrison T, Sondak VK, Gajewski TF, Khushalani NI, Luke JJJournal of clinical oncology : official journal of the American Society of Clinical OncologyPembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol. 2021 08 20; 39(24):2647-2655.J Clin Oncol2021-05-04T00:00:002021Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.21603121Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Rolle CE, Kanteti R, Ferguson BD, Hasina R, Gangadhar TC, Salama AK, Arif Q, Kirchner C, Mendonca E, Campbell N, Limvorasak S, Villaflor V, Hensing TA, Krausz T, Vokes EE, Husain AN, Ferguson MK, Karrison TG, Salgia RJournal of clinical bioinformaticsProteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database. J Clin Bioinforma. 2011 Feb 28; 1(8):1-11.J Clin Bioinforma2011-02-28T00:00:002011Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database.18217206Odenike OM, Larson RA, Gajria D, Dolan ME, Delaney SM, Karrison TG, Ratain MJ, Stock WInvestigational new drugsPhase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9.Invest New Drugs2008-01-24T00:00:002008Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.21861128RamÃrez J, Wu K, Janisch L, Karrison T, House LK, Innocenti F, Cohen EE, Ratain MJCancer chemotherapy and pharmacologyThe effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1629-32.Cancer Chemother Pharmacol2011-08-23T00:00:002011The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients.19649772Choong NW, Kozloff M, Taber D, Hu HS, Wade J, Ivy P, Karrison TG, Dekker A, Vokes EE, Cohen EEInvestigational new drugsPhase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs. 2010 Oct; 28(5):677-83.Invest New Drugs2009-08-04T00:00:002009Phase II study of sunitinib malate in head and neck squamous cell carcinoma.20034979Pytel P, Karrison T, Tonsgard JH, Krausz T, Montag AGInternational journal of surgical pathologyNeoplasms with schwannian differentiation express transcription factors known to regulate normal schwann cell development. Int J Surg Pathol. 2010 Dec; 18(6):449-57.Int J Surg Pathol2009-12-24T00:00:002009Neoplasms with schwannian differentiation express transcription factors known to regulate normal schwann cell development.22021924Boyer K, Hill D, Mui E, Wroblewski K, Karrison T, Dubey JP, Sautter M, Noble AG, Withers S, Swisher C, Heydemann P, Hosten T, Babiarz J, Lee D, Meier P, McLeod R, Toxoplasmosis Study GroupClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaUnrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America. Clin Infect Dis. 2011 Dec; 53(11):1081-9.Clin Infect Dis2011-10-21T00:00:002011Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America.18317595Zhang B, Karrison T, Rowley DA, Schreiber HThe Journal of clinical investigationIFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest. 2008 Apr; 118(4):1398-404.J Clin Invest2008-04-01T00:00:002008IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.3276729Polonsky KS, Given BD, Hirsch L, Shapiro ET, Tillil H, Beebe C, Galloway JA, Frank BH, Karrison T, Van Cauter EThe Journal of clinical investigationQuantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest. 1988 Feb; 81(2):435-41.J Clin Invest1988-02-01T00:00:001988Quantitative study of insulin secretion and clearance in normal and obese subjects.3514322Polonsky K, Frank B, Pugh W, Addis A, Karrison T, Meier P, Tager H, Rubenstein ADiabetesThe limitations to and valid use of C-peptide as a marker of the secretion of insulin. Diabetes. 1986 Apr; 35(4):379-86.Diabetes1986-04-01T00:00:001986The limitations to and valid use of C-peptide as a marker of the secretion of insulin.7512294Zeng Y, Torre MA, Karrison T, Thistlethwaite JRTransplantationThe correlation between donor characteristics and the success of human islet isolation. Transplantation. 1994 Mar 27; 57(6):954-8.Transplantation1994-03-27T00:00:001994The correlation between donor characteristics and the success of human islet isolation.7615824Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KSThe Journal of clinical investigationInsulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest. 1995 Jul; 96(1):520-7.J Clin Invest1995-07-01T00:00:001995Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus.Authorship 147821334168049Foster CC, Fleming GF, Karrison TG, Liao CY, Desai AV, Moroney JW, Ratain MJ, Nanda R, Polite BN, Hahn OM, O'Donnell PH, Vokes EE, Kindler HL, Hseu R, Janisch LA, Dai J, Hoffman MD, Weichselbaum RR, Pitroda SP, Chmura SJ, Luke JJClinical cancer research : an official journal of the American Association for Cancer ResearchPhase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.Clin Cancer Res2021-06-24T00:00:002021Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.2452685Sagher D, Karrison T, Schwartz JL, Larson R, Meier P, Strauss BCancer researchLow O6-alkylguanine DNA alkyltransferase activity in the peripheral blood lymphocytes of patients with therapy-related acute nonlymphocytic leukemia. Cancer Res. 1988 Jun 01; 48(11):3084-9.Cancer Res1988-06-01T00:00:001988Low O6-alkylguanine DNA alkyltransferase activity in the peripheral blood lymphocytes of patients with therapy-related acute nonlymphocytic leukemia.22287601Sharma MR, Karrison TG, Jin Y, Bies RR, Maitland ML, Stadler WM, Ratain MJClinical cancer research : an official journal of the American Association for Cancer ResearchResampling phase III data to assess phase II trial designs and endpoints. Clin Cancer Res. 2012 Apr 15; 18(8):2309-15.Clin Cancer Res2012-01-27T00:00:002012Resampling phase III data to assess phase II trial designs and endpoints.3340717Schwartz JL, Giovanazzi SM, Karrison T, Jones C, Grdina DJRadiation research2-[(Aminopropyl)amino] ethanethiol-mediated reductions in 60Co gamma-ray and fission-spectrum neutron-induced chromosome damage in V79 cells. Radiat Res. 1988 Jan; 113(1):145-54.Radiat Res1988-01-01T00:00:0019882-[(Aminopropyl)amino] ethanethiol-mediated reductions in 60Co gamma-ray and fission-spectrum neutron-induced chromosome damage in V79 cells.Authorship 1482626Authorship 148331334320785Major A, Kline J, Karrison TG, Fishkin PAS, Kimball AS, Petrich AM, Nattam S, Rao K, Sleckman BG, Cohen K, Besien KV, Rapoport AP, Smith SMHaematologicaPhase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. Haematologica. 2022 07 01; 107(7):1608-1618.Haematologica2022-07-01T00:00:002022Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.3458227Weichselbaum RR, Dahlberg W, Beckett M, Karrison T, Miller D, Clark J, Ervin TJProceedings of the National Academy of Sciences of the United States of AmericaRadiation-resistant and repair-proficient human tumor cells may be associated with radiotherapy failure in head- and neck-cancer patients. Proc Natl Acad Sci U S A. 1986 Apr; 83(8):2684-8.Proc Natl Acad Sci U S A1986-04-01T00:00:001986Radiation-resistant and repair-proficient human tumor cells may be associated with radiotherapy failure in head- and neck-cancer patients.22181983Tretiakova M, Salama AK, Karrison T, Ferguson MK, Husain AN, Vokes EE, Salgia RJournal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and CancerMET and phosphorylated MET as potential biomarkers in lung cancer. J Environ Pathol Toxicol Oncol. 2011; 30(4):341-54.J Environ Pathol Toxicol Oncol2011-01-01T00:00:002011MET and phosphorylated MET as potential biomarkers in lung cancer.22415314Schreiber K, Arina A, Engels B, Spiotto MT, Sidney J, Sette A, Karrison TG, Weichselbaum RR, Rowley DA, Schreiber HClinical cancer research : an official journal of the American Association for Cancer ResearchSpleen cells from young but not old immunized mice eradicate large established cancers. Clin Cancer Res. 2012 May 01; 18(9):2526-33.Clin Cancer Res2012-03-13T00:00:002012Spleen cells from young but not old immunized mice eradicate large established cancers.22499837McLeod R, Boyer KM, Lee D, Mui E, Wroblewski K, Karrison T, Noble AG, Withers S, Swisher CN, Heydemann PT, Sautter M, Babiarz J, Rabiah P, Meier P, Grigg ME, Toxoplasmosis Study GroupClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaPrematurity and severity are associated with Toxoplasma gondii alleles (NCCCTS, 1981-2009). Clin Infect Dis. 2012 Jun; 54(11):1595-605.Clin Infect Dis2012-04-11T00:00:002012Prematurity and severity are associated with Toxoplasma gondii alleles (NCCCTS, 1981-2009).3519643Polonsky KS, Given BD, Pugh W, Licinio-Paixao J, Thompson JE, Karrison T, Rubenstein AHThe Journal of clinical endocrinology and metabolismCalculation of the systemic delivery rate of insulin in normal man. J Clin Endocrinol Metab. 1986 Jul; 63(1):113-8.J Clin Endocrinol Metab1986-07-01T00:00:001986Calculation of the systemic delivery rate of insulin in normal man.22100149Cohen EE, Subramanian J, Gao F, Szeto L, Kozloff M, Faoro L, Karrison T, Salgia R, Govindan R, Vokes EEClinical lung cancerTargeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer. 2012 Mar; 13(2):123-8.Clin Lung Cancer2011-11-18T00:00:002011Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.2177980Strauss B, Sagher D, Karrison T, Schwartz J, Larson R, Williams SBasic life sciencesMethyl transferase activity in secondary leukemia. Basic Life Sci. 1990; 53:277-89.Basic Life Sci1990-01-01T00:00:001990Methyl transferase activity in secondary leukemia.Authorship 149633334500113Bestvina CM, Pointer KB, Karrison T, Al-Hallaq H, Hoffman PC, Jelinek MJ, Juloori A, Melotek JM, Murgu S, Partouche J, Vokes EE, Weichselbaum RR, Pitroda SP, Patel JD, Chmura SJJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerA Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140.J Thorac Oncol2021-09-06T00:00:002021A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study.6389599Polonsky KS, Pugh W, Jaspan JB, Cohen DM, Karrison T, Tager HS, Rubenstein AHThe Journal of clinical investigationC-peptide and insulin secretion. Relationship between peripheral concentrations of C-peptide and insulin and their secretion rates in the dog. J Clin Invest. 1984 Nov; 74(5):1821-9.J Clin Invest1984-11-01T00:00:001984C-peptide and insulin secretion. Relationship between peripheral concentrations of C-peptide and insulin and their secretion rates in the dog.1284591Vijayakumar S, Karrison T, Weichselbaum RR, Chan S, Quadri SF, Awan AMCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyRacial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Cancer Epidemiol Biomarkers Prev. 1992 Nov-Dec; 1(7):541-5.Cancer Epidemiol Biomarkers Prev1992-11-01T00:00:001992Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer.18158263Vokes TJ, Pham A, Wilkie J, Kocherginsky M, Ma SL, Chinander M, Karrison T, Bris O, Giger MLJournal of clinical densitometry : the official journal of the International Society for Clinical DensitometryReproducibility and sources of variability in radiographic texture analysis of densitometric calcaneal images. J Clin Densitom. 2008 Apr-Jun; 11(2):211-20.J Clin Densitom2007-12-26T00:00:002007Reproducibility and sources of variability in radiographic texture analysis of densitometric calcaneal images.18650079Undevia SD, Innocenti F, Ramirez J, House L, Desai AA, Skoog LA, Singh DA, Karrison T, Kindler HL, Ratain MJEuropean journal of cancer (Oxford, England : 1990)A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer. 2008 Aug; 44(12):1684-92.Eur J Cancer2008-07-21T00:00:002008A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.7023761Check IJ, Hunter RL, Karrison T, DeMeester TR, Golomb HM, Vardiman JClinical and experimental immunologyPrognostic significance of immunological tests in lung cancer. Clin Exp Immunol. 1981 Feb; 43(2):362-9.Clin Exp Immunol1981-02-01T00:00:001981Prognostic significance of immunological tests in lung cancer.Authorship 150018634570085Truong TM, Apfelbaum JL, Schierer E, Danahey K, Borden BA, Karrison T, Shahul S, Anitescu M, Gerlach R, Knoebel RW, Meltzer DO, Ratain MJ, O'Donnell PHPharmacogenetics and genomicsAnesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care. Pharmacogenet Genomics. 2022 04 01; 32(3):79-86.Pharmacogenet Genomics2022-04-01T00:00:002022Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care.19815620Palakodeti A, Lucas I, Jiang Y, Young DJ, Fernald AA, Karrison T, Le Beau MMHuman molecular geneticsImpaired replication dynamics at the FRA3B common fragile site. Hum Mol Genet. 2010 Jan 01; 19(1):99-110.Hum Mol Genet2010-01-01T00:00:002010Impaired replication dynamics at the FRA3B common fragile site.2548719Sagher D, Karrison T, Schwartz JL, Larson RA, Strauss BCancer researchHeterogeneity of O6-alkylguanine-DNA alkyltransferase activity in peripheral blood lymphocytes: relationship between this activity in lymphocytes and in lymphoblastoid lines from normal controls and from patients with Hodgkin's disease or non-Hodgkin's lymphoma. Cancer Res. 1989 Oct 01; 49(19):5339-44.Cancer Res1989-10-01T00:00:001989Heterogeneity of O6-alkylguanine-DNA alkyltransferase activity in peripheral blood lymphocytes: relationship between this activity in lymphocytes and in lymphoblastoid lines from normal controls and from patients with Hodgkin's disease or non-Hodgkin's lymphoma.21304468Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Kanteti R, Ferguson B, Gangadhar T, Hensing T, Hasina R, Husain A, Ferguson M, Karrison T, Salgia RJournal of visualized experiments : JoVEGeneration of comprehensive thoracic oncology database--tool for translational research. J Vis Exp. 2011 Jan 22; (47).J Vis Exp2011-01-22T00:00:002011Generation of comprehensive thoracic oncology database--tool for translational research.3279811Tillil H, Shapiro ET, Miller MA, Karrison T, Frank BH, Galloway JA, Rubenstein AH, Polonsky KSThe American journal of physiologyDose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans. Am J Physiol. 1988 Mar; 254(3 Pt 1):E349-57.Am J Physiol1988-03-01T00:00:001988Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans.9145973Gerber GS, Goldfischer ER, Karrison TG, Bales GTUrologySerum creatinine measurements in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 1997 May; 49(5):697-702.Urology1997-05-01T00:00:001997Serum creatinine measurements in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.15570084Zimmerman TM, Harlin H, Odenike OM, Berk S, Sprague E, Karrison T, Stock W, Larson RA, Ratain MJ, Gajewski TFJournal of clinical oncology : official journal of the American Society of Clinical OncologyDose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22.J Clin Oncol2004-12-01T00:00:002004Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.17530685Booth S, Chohan S, Curran JC, Karrison T, Schmitz A, Utset TOArthritis and rheumatismWhole blood viscosity and arterial thrombotic events in patients with systemic lupus erythematosus. Arthritis Rheum. 2007 Jun 15; 57(5):845-50.Arthritis Rheum2007-06-15T00:00:002007Whole blood viscosity and arterial thrombotic events in patients with systemic lupus erythematosus.Authorship 15063315Authorship 1507072Authorship 1507131834700464Dahl DM, Rodgers J, Shipley WU, Michaelson D, Wu CL, Parker W, Efstathiou JA, Jani A, Cury F, Hudes R, Michalski JM, Hartford AC, Song D, Citrin DE, Karrison TG, Feng FYInternational journal of radiation oncology, biology, physicsNRG Oncology/RTOG 0926: Phase II Protocol for Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):S133-S134.Int J Radiat Oncol Biol Phys2021-11-01T00:00:002021NRG Oncology/RTOG 0926: Phase II Protocol for Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging.34700528Movsas B, Rodgers J, Elshaikh MA, Martinez AA, Morton G, Krauss DJ, Yan D, Citrin DE, Hershatter B, Michalski JM, Ellis RJ, Kavadi VS, Gore EM, Gustafson GS, Schulz CA, Velker V, Olson AC, Karrison TG, Sandler HM, Bruner DWInternational journal of radiation oncology, biology, physicsDose Escalated Radiotherapy (RT) Alone or in Combination With Short-Term Total Androgen Suppression (TAS) for Intermediate Risk Prostate Cancer: Patient Reported Outcomes (PROs) From the NRG Oncology/RTOG 0815 Randomized Trial. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):S3.Int J Radiat Oncol Biol Phys2021-11-01T00:00:002021Dose Escalated Radiotherapy (RT) Alone or in Combination With Short-Term Total Androgen Suppression (TAS) for Intermediate Risk Prostate Cancer: Patient Reported Outcomes (PROs) From the NRG Oncology/RTOG 0815 Randomized Trial.34700386Krauss DJ, Karrison TG, Martinez AA, Morton G, Yan D, Bruner DW, Movsas B, Elshaikh MA, Citrin DE, Hershatter B, Michalski JM, Efstathiou JA, Currey AD, Kavadi VS, Cury F, Lock MI, Raben A, Sandler HMInternational journal of radiation oncology, biology, physicsDose Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Suppression for Intermediate Risk Prostate Cancer: Outcomes From the NRG Oncology/RTOG 0815 Randomized Trial. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):S1.Int J Radiat Oncol Biol Phys2021-11-01T00:00:002021Dose Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Suppression for Intermediate Risk Prostate Cancer: Outcomes From the NRG Oncology/RTOG 0815 Randomized Trial.19546413Casalino LP, Dunham D, Chin MH, Bielang R, Kistner EO, Karrison TG, Ong MK, Sarkar U, McLaughlin MA, Meltzer DOArchives of internal medicineFrequency of failure to inform patients of clinically significant outpatient test results. Arch Intern Med. 2009 Jun 22; 169(12):1123-9.Arch Intern Med2009-06-22T00:00:002009Frequency of failure to inform patients of clinically significant outpatient test results.20395787Chung EK, Posadas EM, Kasza K, Karrison T, Manchen E, Hahn OM, Stadler WMAmerican journal of clinical oncologyA phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. Am J Clin Oncol. 2011 Apr; 34(2):150-4.Am J Clin Oncol2011-04-01T00:00:002011A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma.20434849Nichols MA, Mell LK, Hasselle MD, Karrison TG, MacDermed D, Meriwether A, Witt ME, Weichselbaum RR, Chmura SJInternational journal of radiation oncology, biology, physicsOutcomes in black patients with early breast cancer treated with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2011 Feb 01; 79(2):392-9.Int J Radiat Oncol Biol Phys2010-04-29T00:00:002010Outcomes in black patients with early breast cancer treated with breast conservation therapy.21543897Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Brägelmann J, Seiwert T, Sanicola M, Henderson L, Grushko TA, Olopade O, Karrison T, Bang YJ, Kim WH, Tretiakova M, Vokes E, Frank DA, Kindler HL, Huet H, Salgia RCancer biology & therapyRON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011 Jul 01; 12(1):9-46.Cancer Biol Ther2011-07-01T00:00:002011RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.22006050Ward JE, Karrison T, Chatta G, Hussain M, Shevrin D, Szmulewitz RZ, O'Donnell PH, Stadler WM, Posadas EMProstate cancer and prostatic diseasesA randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):87-92.Prostate Cancer Prostatic Dis2011-10-18T00:00:002011A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.22183212Romero IL, McCormick A, McEwen KA, Park S, Karrison T, Yamada SD, Pannain S, Lengyel EObstetrics and gynecologyRelationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 2012 Jan; 119(1):61-7.Obstet Gynecol2012-01-01T00:00:002012Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity.22665541Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Jänne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG, Vogelzang NJ, Chen HX, Stadler WM, Vokes EEJournal of clinical oncology : official journal of the American Society of Clinical OncologyMulticenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012 Jul 10; 30(20):2509-15.J Clin Oncol2012-06-04T00:00:002012Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.3511094Polonsky KS, Licinio-Paixao J, Given BD, Pugh W, Rue P, Galloway J, Karrison T, Frank BThe Journal of clinical investigationUse of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest. 1986 Jan; 77(1):98-105.J Clin Invest1986-01-01T00:00:001986Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients.7505422Lester LA, Kraut J, Lloyd-Still J, Karrison T, Mott C, Billstrand C, Lemke A, Ober CPediatricsDelta F508 genotype does not predict disease severity in an ethnically diverse cystic fibrosis population. Pediatrics. 1994 Jan; 93(1):114-8.Pediatrics1994-01-01T00:00:001994Delta F508 genotype does not predict disease severity in an ethnically diverse cystic fibrosis population.Authorship 1518516Authorship 1519621334980038Rosenberg AJ, Izumchenko E, Pearson A, Gooi Z, Blair E, Karrison T, Juloori A, Ginat D, Cipriani N, Lingen M, Sloane H, Edelstein DL, Keyser K, Fredebohm J, Holtrup F, Jones FS, Haraf D, Agrawal N, Vokes EEBMC cancerProspective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer. 2022 Jan 03; 22(1):17.BMC Cancer2022-01-03T00:00:002022Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment.34988836Dhiman A, Vining CC, Witmer HDD, Sood D, Shergill A, Kindler H, Roggin KK, Posner MC, Ahmed OS, Liauw S, Pitroda S, Liao CY, Karrison T, Weichselbaum R, Polite B, Eng OS, Catenacci DVT, Turaga KKAnnals of surgical oncologyPhase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels. Ann Surg Oncol. 2022 Jan 05.Ann Surg Oncol2022-01-05T00:00:002022Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels.Authorship 152159235018550Giurcanu MC, Karrison TGLifetime data analysisNonparametric inference in the accelerated failure time model using restricted means. Lifetime Data Anal. 2022 01; 28(1):23-39.Lifetime Data Anal2022-01-12T00:00:002022Nonparametric inference in the accelerated failure time model using restricted means.Authorship 1526406Authorship 152540935090043Reizine NM, Danahey K, Truong TM, George D, House LK, Karrison TG, van Wijk XMR, Yeo KJ, Ratain MJ, O'Donnell PHCancerClinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing. Cancer. 2022 Apr 15; 128(8):1649-1657.Cancer2022-01-28T00:00:002022Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.35110415Serritella AV, Shevrin D, Heath EI, Wade JL, Martinez E, Anderson A, Schonhoft J, Chu YL, Karrison T, Stadler WM, Szmulewitz RZClinical cancer research : an official journal of the American Association for Cancer ResearchPhase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1549-1559.Clin Cancer Res2022-04-14T00:00:002022Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer.35213469Truong TM, Apfelbaum JL, Danahey K, Schierer E, Ludwig J, George D, House L, Karrison T, Shahul S, Anitescu M, Choksi A, Hartman S, Knoebel RW, van Wijk XMR, Yeo KJ, Meltzer DO, Ratain MJ, O'Donnell PHAnesthesia and analgesiaPilot Findings of Pharmacogenomics in Perioperative Care: Initial Results From the First Phase of the ImPreSS Trial. Anesth Analg. 2022 11 01; 135(5):929-940.Anesth Analg2022-02-25T00:00:002022Pilot Findings of Pharmacogenomics in Perioperative Care: Initial Results From the First Phase of the ImPreSS Trial.Authorship 154868235569466Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, Wefel JS, Martin AG, Michalski JM, Angyalfi SJ, Lukka H, Faria SL, Rodrigues GB, Beauchemin MC, Lee RJ, Seaward SA, Allen AM, Monitto DC, Seiferheld W, Sartor O, Feng F, Sandler HMLancet (London, England)The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022 05 14; 399(10338):1886-1901.Lancet2022-05-14T00:00:002022The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.Authorship 1552082Authorship 155242335665495Desai AV, Applebaum MA, Karrison TG, Oppong A, Yuan C, Berg KR, MacQuarrie K, Sokol E, Hall AG, Pinto N, Wolfe I, Mody R, Shusterman S, Smith V, Foster JH, Nassin M, LaBelle JL, Bagatell R, Cohn SLCancerEfficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer. 2022 08 01; 128(15):2967-2977.Cancer2022-06-06T00:00:002022Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease.35675855Hall WA, Karrison TG, Rosenthal SA, Amin MB, Gomella LG, Purdy JA, Sartor AO, Michalski JM, Garzotto MG, Bergom C, Jani AB, Lawton CAF, Simko JP, Moore JK, Gore EM, Lee WR, Nguyen PL, Danielson BL, Sandler HM, Feng FYInternational journal of radiation oncology, biology, physicsThe Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521. Int J Radiat Oncol Biol Phys. 2022 10 01; 114(2):266-274.Int J Radiat Oncol Biol Phys2022-06-05T00:00:002022The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521.Authorship 155399335728059Anderson DR, Stock W, Karrison TG, Leader ABlood advancesD-dimer and risk for thrombosis in adults with newly diagnosed acute lymphoblastic leukemia. Blood Adv. 2022 09 13; 6(17):5146-5151.Blood Adv2022-09-13T00:00:002022D-dimer and risk for thrombosis in adults with newly diagnosed acute lymphoblastic leukemia.D012107Concepts & IdeasLiving BeingsProcedures2505940.748878Research DesignAuthorship 15626013Authorship 156207235862034Derman BA, Kansagra A, Zonder J, Stefka AT, Grinblatt DL, Anderson LD, Gurbuxani S, Narula S, Rayani S, Major A, Kin A, Jiang K, Karrison T, Jasielec J, Jakubowiak AJJAMA oncologyElotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 09 01; 8(9):1278-1286.JAMA Oncol2022-09-01T00:00:002022Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.35869002Chablani PV, Karrison T, Stadler WMClinical genitourinary cancerEvaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors. Clin Genitourin Cancer. 2022 Dec; 20(6):510-514.Clin Genitourin Cancer2022-06-11T00:00:002022Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors.Public Health SciencesD016019Concepts & Ideas43415360.742939Survival Analysis24637941Karovic S, Wen Y, Karrison TG, Bakris GL, Levine MR, House LK, Wu K, Thomeas V, Rudek MA, Wright JJ, Cohen EE, Fleming GF, Ratain MJ, Maitland MLClinical pharmacology and therapeuticsSorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther. 2014 Jul; 96(1):27-35.Clin Pharmacol Ther2014-03-17T00:00:002014Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.23900000Bhatta SS, Wroblewski KE, Agarwal KL, Sit L, Cohen EE, Seiwert TY, Karrison T, Bakris GL, Ratain MJ, Vokes EE, Maitland MLThe oncologistEffects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist. 2013; 18(8):965-70.Oncologist2013-07-30T00:00:002013Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.Authorship 15823113Authorship 15877527Authorship 1583129Authorship 1589683Authorship 159446236034212FelÃn MS, Wang K, Moreira A, Grose A, Leahy K, Zhou Y, Clouser FA, Siddiqui M, Leong N, Goodall P, Michalowski M, Ismail M, Christmas M, Schrantz S, Caballero Z, Norero X, Estripeaut D, Ellis D, Raggi C, Castro C, Moossazadeh D, Ramirez M, Pandey A, Ashi K, Dovgin S, Dixon A, Li X, Begeman I, Heichman S, Lykins J, Villalobos-Cerrud D, Fabrega L, Montalvo JLS, Mendivil C, Quijada MR, Fernández-Pirla S, de La Guardia V, Wong D, de Guevara ML, Flores C, Borace J, GarcÃa A, Caballero N, Rengifo-Herrera C, de Saez MTM, Politis M, Wroblewski K, Karrison T, Ross S, Dogra M, Dhamsania V, Graves N, Kirchberg M, Mathur K, Aue A, Restrepo CM, Llanes A, Guzman G, Rebellon A, Boyer K, Heydemann P, Noble AG, Swisher C, Rabiah P, Withers S, Hull T, Su C, Blair M, Latkany P, Mui E, Vasconcelos-Santos DV, Villareal A, Perez A, Galvis CAN, Montes MV, Perez NIC, Ramirez M, Chittenden C, Wang E, Garcia-López LL, Muñoz-Ortiz J, Rivera-Valdivia N, Bohorquez-Granados MC, de-la-Torre GC, Padrieu G, Hernandez JDV, Celis-Giraldo D, Dávila JAA, Torres E, Oquendo MM, Arteaga-Rivera JY, Nicolae DL, Rzhetsky A, Roizen N, Stillwaggon E, Sawers L, Peyron F, Wallon M, Chapey E, Levigne P, Charter C, De Frias M, Montoya J, Press C, Ramirez R, Contopoulos-Ioannidis D, Maldonado Y, Liesenfeld O, Gomez C, Wheeler K, Holfels E, Frim D, McLone D, Penn R, Cohen W, Zehar S, McAuley J, Limonne D, Houze S, Abraham S, Piarroux R, Tesic V, Beavis K, Abeleda A, Sautter M, El Mansouri B, El Bachir A, Amarir F, El Bissati K, de-la-Torre A, Britton G, Motta J, Ortega-Barria E, Romero IL, Meier P, Grigg M, Gómez-MarÃn J, Kosagisharaf JR, Llorens XS, Reyes O, McLeod RCurrent pediatrics reportsBuilding Programs to Eradicate Toxoplasmosis Part I: Introduction and Overview. Curr Pediatr Rep. 2022; 10(3):57-92.Curr Pediatr Rep2022-08-22T00:00:002022Building Programs to Eradicate Toxoplasmosis Part I: Introduction and Overview.36116477Pollack A, Karrison TG, Feng F, Sartor O, Sandler HMLancet (London, England)The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy - Authors' reply. Lancet. 2022 09 17; 400(10356):885-886.Lancet2022-09-17T00:00:002022The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy - Authors' reply.35930113Dhiman A, Vining CC, Witmer HDD, Sood D, Shergill A, Kindler H, Roggin KK, Posner MC, Ahmed OS, Liauw S, Pitroda S, Liao CY, Karrison T, Weichselbaum R, Polite B, Eng OS, Catenacci DVT, Turaga KKAnnals of surgical oncologyASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels. Ann Surg Oncol. 2022 Dec; 29(Suppl 3):616-617.Ann Surg Oncol2022-12-01T00:00:002022ASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels.35973200Godfrey J, Liu H, Yu J, Tallarico M, Curran E, Artz A, Riedell PA, Stock W, Karrison T, Fitzpatrick C, Venkataraman G, Cooper A, Smith SM, Bishop MR, Kline JBlood advancesPembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2023 03 28; 7(6):963-970.Blood Adv2023-03-28T00:00:002023Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation.36194164Nathan CO, Hayes DN, Karrison T, Harismendy O, Flores JM, Moore-Medlin T, Vokes EE, Gutkind JS, Neupane P, Mills G, Sargi Z, Seiwert T, Grilley-Olson J, Day T, Gillison M, Wade JL, Feldman L, Jha G, Kozloff M, O'Leary M, Worden FP, Cohen EEWClinical cancer research : an official journal of the American Association for Cancer ResearchA Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. Clin Cancer Res. 2022 12 01; 28(23):5040-5048.Clin Cancer Res2022-12-01T00:00:002022A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck.Authorship 160591736726221Derman BA, Chari A, Zonder J, Major A, Stefka AT, Jiang K, Karrison T, Jasielec J, Jakubowiak AEuropean journal of haematologyA phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma. Eur J Haematol. 2023 May; 110(5):564-570.Eur J Haematol2023-02-15T00:00:002023A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.Authorship 161147336806414Tran MC, Strohbehn GW, Karrison TG, Rouhani SJ, Segal JP, Shergill A, Hoffman PC, Patel JD, Garassino MC, Vokes EE, Bestvina CMClinical lung cancerBrief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression. Clin Lung Cancer. 2023 05; 24(3):e117-e121.Clin Lung Cancer2023-01-25T00:00:002023Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression.http://bcrisktool.uchicago.edu/Breast Cancer Risk Calculator for Africanshttp://abcs.uchicago.eduABCS database24178622Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike OClinical cancer research : an official journal of the American Association for Cancer ResearchPhase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8.Clin Cancer Res2013-10-31T00:00:002013Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.25361984Das LC, Karrison TG, Witt ME, Muller C, Stenson K, Blair EA, Cohen EEW, Seiwert TY, Haraf DJ, Vokes EEAnnals of oncology : official journal of the European Society for Medical OncologyComparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. Ann Oncol. 2015 Jan; 26(1):198-205.Ann Oncol2014-10-30T00:00:002014Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades.24039273Karrison TG, Ratain MJ, Stadler WM, Rosner GLThe American statisticianEstimation of Progression-Free Survival for All Treated Patients in the Randomized Discontinuation Trial Design. Am Stat. 2012; 66(3):155-162.Am Stat2012-01-01T00:00:002012Estimation of Progression-Free Survival for All Treated Patients in the Randomized Discontinuation Trial Design.24958824Innocenti F, Schilsky RL, RamÃrez J, Janisch L, Undevia S, House LK, Das S, Wu K, Turcich M, Marsh R, Karrison T, Maitland ML, Salgia R, Ratain MJJournal of clinical oncology : official journal of the American Society of Clinical OncologyDose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014 Aug 01; 32(22):2328-34.J Clin Oncol2014-06-23T00:00:002014Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.25049329Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EEJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 01; 32(25):2735-43.J Clin Oncol2014-07-21T00:00:002014Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.24386952Maitland ML, Levine MR, Lacouture ME, Wroblewski KE, Chung CH, Gordon IO, Szeto L, Ratko G, Soltani K, Kozloff MF, Hoffman PC, Salgia R, Carbone DP, Karrison TG, Vokes EEBMC cancerEvaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer. 2014 Jan 04; 14:5.BMC Cancer2014-01-04T00:00:002014Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.Authorship 16213318Authorship 1621403Authorship 1621477Authorship 1624168Authorship 16312820Authorship 16204620Authorship 1623825Authorship 163129237104723Movsas B, Rodgers JP, Elshaikh MA, Martinez AA, Morton GC, Krauss DJ, Yan D, Citrin DE, Hershatter BW, Michalski JM, Ellis RJ, Kavadi VS, Gore EM, Gustafson GS, Schulz CA, Velker VM, Olson AC, Cury FL, Papagikos MA, Karrison TG, Sandler HM, Bruner DWJournal of clinical oncology : official journal of the American Society of Clinical OncologyDose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial. J Clin Oncol. 2023 06 10; 41(17):3217-3224.J Clin Oncol2023-04-27T00:00:002023Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial.37104748Krauss DJ, Karrison T, Martinez AA, Morton G, Yan D, Bruner DW, Movsas B, Elshaikh M, Citrin D, Hershatter B, Michalski JM, Efstathiou JA, Currey A, Kavadi VS, Cury FL, Lock M, Raben A, Seaward SA, El-Gayed A, Rodgers JP, Sandler HMJournal of clinical oncology : official journal of the American Society of Clinical OncologyDose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial. J Clin Oncol. 2023 06 10; 41(17):3203-3216.J Clin Oncol2023-04-27T00:00:002023Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial.37137444Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FYInternational journal of radiation oncology, biology, physicsGenomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2023 10 01; 117(2):370-377.Int J Radiat Oncol Biol Phys2023-05-02T00:00:002023Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial.37183819Korpics MC, Onderdonk BE, Dadey RE, Hara JH, Karapetyan L, Zha Y, Karrison TG, Olson AC, Fleming GF, Weichselbaum RR, Bao R, Chmura SJ, Luke JJThe Journal of clinical investigationPartial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases. J Clin Invest. 2023 05 15; 133(10).J Clin Invest2023-05-15T00:00:002023Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases.37026796Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, Kamdar MK, Haverkos BM, Godfrey J, Babcook MA, Voorhees TJ, Carlson S, Gaut D, Oliai C, Romancik JT, Winter AM, Hill BT, Bansal R, Villasboas Bisneto JC, Nizamuddin IA, Karmali R, Fitzgerald LA, Stephens DM, Pophali PA, Trabolsi A, Schatz JH, Hu M, Bachanova V, Slade MJ, Singh N, Ahmed N, McGuirk JP, Bishop MR, Riedell PA, Kline JBlood advancesEfficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Adv. 2023 08 22; 7(16):4528-4538.Blood Adv2023-08-22T00:00:002023Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.37179241Sartor O, Karrison TG, Sandler HM, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Jones CU, Horwitz EM, Rodgers JP, Feng FY, Rosenthal SAEuropean urologyAndrogen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial. Eur Urol. 2023 08; 84(2):156-163.Eur Urol2023-05-12T00:00:002023Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.37182801Rosenberg AJ, Liao CY, Karrison T, de Souza JA, Worden FP, Libao B, Krzyzanowska MK, Hayes DN, Winquist E, Saloura V, Prescott K, Villaflor VM, Seiwert TY, Schechter RB, Stadler WM, Cohen EEW, Vokes EEAnnals of oncology : official journal of the European Society for Medical OncologyA multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. Ann Oncol. 2023 08; 34(8):714-722.Ann Oncol2023-05-13T00:00:002023A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.Authorship 1639874Authorship 163998237437522Kass-Hout T, Morsi RZ, Thind S, Karrison T, Lee H, Nahab F, Gupta R, Carrión-Penagos J, Awad IA, Coleman E, Brorson JR, McKoy C, Morales J, Mendelson S, Mansour A, Prabhakaran SJournal of stroke and cerebrovascular diseases : the official journal of National Stroke AssociationUnderlying intracranial atherosclerotic disease is associated with worse outcomes in acute large vessel occlusion undergoing endovascular thrombectomy. J Stroke Cerebrovasc Dis. 2023 Aug; 32(8):107227.J Stroke Cerebrovasc Dis2023-07-10T00:00:002023Underlying intracranial atherosclerotic disease is associated with worse outcomes in acute large vessel occlusion undergoing endovascular thrombectomy.37442672Dahl DM, Karrison TG, Michaelson MD, Pham HT, Wu CL, Swanson GP, Shipley WU, Vuky J, Lee RJ, Zietman AL, Souhami L, Chang BK, Deming RL, Ellerton JA, Sandler HM, Rodgers JP, Feng FY, Efstathiou JAEuropean urology oncologyLong-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation. Eur Urol Oncol. 2024 Feb; 7(1):83-90.Eur Urol Oncol2023-07-11T00:00:002023Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation.MedicineUniversity of ChicagoDezhengHuo02p8BIEdHO3VhXIqYlXqvXD598K+6LJRPnx+Yw==Dezheng Huo41.78927490000000-87.60125000000000130Huo, DezhengProfessorEzraCohenEzra Cohen41.78927490000000-87.601250000000001350Cohen, EzraASSOCIATE PROFESSORR. TamaraKonetzkaw2lmBaQBA+f5mX9lbFLmvWfp+4Wo6r1Xc3h9eaOOFmI=R. Tamara Konetzka41.78927490000000-87.601250000000001363Konetzka, R. TamaraProfessorMark J.RatainMark J. Ratain41.78927490000000-87.601250000000001401Ratain, Mark J.ProfessorWalter M.StadlerWalter M. Stadler41.78927490000000-87.601250000000001904Stadler, Walter M.ProfessorEverett E.VokesEverett E. Vokes41.78927490000000-87.601250000000001920Vokes, Everett E.ProfessorRaviSalgiaRavi Salgia41.78927490000000-87.601250000000001937Salgia, RaviEmeritus/Emerita, ProfessorNingqiHouNingqi Hou41.78927490000000-87.601250000000002021Hou, NingqiPostdoctoral Scholar2.340510.003141291164research areas2.755650.00313917232coauthor of170.07125.923860similar to11295selected publicationsHedyKindler32lgBaUZHP75hHlsaUXv9Gq0+s+oHedy Kindler41.78927490000000-87.601250000000002499Kindler, HedyProfessorHongyuanCaoHongyuan Cao41.78927490000000-87.60125000000000552Cao, HongyuanAssistant ProfessorMuhammad G.KibriyaMuhammad G. Kibriya41.78927490000000-87.60125000000000814Kibriya, Muhammad G.Research Associate ProfessorAuthorship 169621338254183Polley MC, Schwartz D, Karrison T, Dignam JJNeuro-oncologyLeveraging External Control Data in the Design and Analysis of Neuro-Oncology Trials: Pearls and Perils. Neuro Oncol. 2024 Jan 22.Neuro Oncol2024-01-22T00:00:002024Leveraging External Control Data in the Design and Analysis of Neuro-Oncology Trials: Pearls and Perils.Authorship 170629938420615Driscoll RK, Lyne SB, Voce DJ, Maraka S, Gondi V, Chmura SJ, Dixit KS, Kumthekar PU, Karrison TG, Pytel P, Collins JM, Stupp R, Merrell RT, Lukas RV, Yamini BNeuro-oncology advancesA multi-institutional phase I study of acetazolamide with temozolomide in adults with newly diagnosed MGMT-methylated malignant glioma. Neurooncol Adv. 2024 Jan-Dec; 6(1):vdae014.Neurooncol Adv2024-02-01T00:00:002024A multi-institutional phase I study of acetazolamide with temozolomide in adults with newly diagnosed MGMT-methylated malignant glioma.true1ASSOCIATE PROFESSORASSOCIATE PROFESSORtrue1Emeritus/Emerita, ProfessorEmeritus/Emerita, Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Research ProfessorResearch Professortrue1Postdoctoral ScholarPostdoctoral Scholartrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1Research Associate ProfessorResearch Associate ProfessorAuthorship 652762Authorship 6595014Authorship 663526Authorship 663377Authorship 665863Authorship 664605Authorship 674403Authorship 666948Authorship 6983211Authorship 696592Authorship 711614Authorship 712517Authorship 714789Authorship 721942Authorship 736756Authorship 7440316Authorship 770265Authorship 670594Authorship 671045Authorship 731452Authorship 772455Authorship 75967725411163Maitland ML, Xu CF, Cheng YC, Kistner-Griffin E, Ryan KA, Karrison TG, Das S, Torgerson D, Gamazon ER, Thomeas V, Levine MR, Wilson PA, Bing N, Liu Y, Cardon LR, Pandite LN, O'Connell JR, Cox NJ, Mitchell BD, Ratain MJ, Shuldiner ARClinical cancer research : an official journal of the American Association for Cancer ResearchIdentification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib. Clin Cancer Res. 2015 Jan 15; 21(2):365-72.Clin Cancer Res2014-11-19T00:00:002014Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib.25349295Sharma MR, Gray E, Goldberg RM, Sargent DJ, Karrison TGJournal of clinical oncology : official journal of the American Society of Clinical OncologyResampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials. J Clin Oncol. 2015 Jan 01; 33(1):36-41.J Clin Oncol2014-10-27T00:00:002014Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.25483416Odenike O, Halpern A, Godley LA, Madzo J, Karrison T, Green M, Fulton N, Mattison RJ, Yee KW, Bennett M, Koval G, Malnassy G, Larson RA, Ratain MJ, Stock WInvestigational new drugsA phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs. 2015 Apr; 33(2):371-9.Invest New Drugs2014-12-09T00:00:002014A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.24304940Gerard DP, Foster DB, Raiser MW, Holden JL, Karrison TGClinical and translational gastroenterologyValidation of a new bowel preparation scale for measuring colon cleansing for colonoscopy: the chicago bowel preparation scale. Clin Transl Gastroenterol. 2013 Dec 05; 4:e43.Clin Transl Gastroenterol2013-12-05T00:00:002013Validation of a new bowel preparation scale for measuring colon cleansing for colonoscopy: the chicago bowel preparation scale.25667282Cohen EE, Kocherginsky M, Karrison T, Seiwert TY, Haraf DJ, Brockstein B, Vokes EEJournal of clinical oncology : official journal of the American Society of Clinical OncologyReply to s. Chakraborty et al. J Clin Oncol. 2015 Mar 10; 33(8):968.J Clin Oncol2015-02-09T00:00:002015Reply to s. Chakraborty et al.24374901Thomeas V, Chow S, Gutierrez JO, Karovic S, Wroblewski K, Kistner-Griffin E, Karrison TG, Maitland MLJournal of clinical pharmacologyTechnical considerations in the development of circulating peptides as pharmacodynamic biomarkers for angiogenesis inhibitors. J Clin Pharmacol. 2014 Jun; 54(6):682-7.J Clin Pharmacol2014-01-17T00:00:002014Technical considerations in the development of circulating peptides as pharmacodynamic biomarkers for angiogenesis inhibitors.25710961Dignam JJ, Karrison TGJournal of the National Cancer InstituteBuilding firm foundations for therapy development. J Natl Cancer Inst. 2015 Mar; 107(3).J Natl Cancer Inst2015-02-20T00:00:002015Building firm foundations for therapy development.24185610Lee SM, Karrison TG, Cox NJ, Im HKGenetic epidemiologyQuantitative allelic test--a fast test for very large association studies. Genet Epidemiol. 2013 Dec; 37(8):831-9.Genet Epidemiol2013-11-01T00:00:002013Quantitative allelic test--a fast test for very large association studies.24440236Prasad SM, Large MC, Patel AR, Famakinwa O, Galocy RM, Karrison T, Shalhav AL, Zagaja GPThe Journal of urologyEarly removal of urethral catheter with suprapubic tube drainage versus urethral catheter drainage alone after robot-assisted laparoscopic radical prostatectomy. J Urol. 2014 Jul; 192(1):89-95.J Urol2014-01-15T00:00:002014Early removal of urethral catheter with suprapubic tube drainage versus urethral catheter drainage alone after robot-assisted laparoscopic radical prostatectomy.24367029Arina A, Schreiber K, Binder DC, Karrison TG, Liu RB, Schreiber HJournal of immunology (Baltimore, Md. : 1950)Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression. J Immunol. 2014 Feb 01; 192(3):1286-93.J Immunol2013-12-23T00:00:002013Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression.24264229Stoddart A, Wang J, Fernald AA, Karrison T, Anastasi J, Le Beau MMBloodCell intrinsic and extrinsic factors synergize in mice with haploinsufficiency for Tp53, and two human del(5q) genes, Egr1 and Apc. Blood. 2014 Jan 09; 123(2):228-38.Blood2013-11-21T00:00:002013Cell intrinsic and extrinsic factors synergize in mice with haploinsufficiency for Tp53, and two human del(5q) genes, Egr1 and Apc.24381225Stoddart A, Fernald AA, Wang J, Davis EM, Karrison T, Anastasi J, Le Beau MMBloodHaploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice. Blood. 2014 Feb 13; 123(7):1069-78.Blood2013-12-31T00:00:002013Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice.24455752Binder DC, Engels B, Arina A, Yu P, Slauch JM, Fu YX, Karrison T, Burnette B, Idel C, Zhao M, Hoffman RM, Munn DH, Rowley DA, Schreiber HCancer immunology researchAntigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. Cancer Immunol Res. 2013 Aug; 1(2):123-33.Cancer Immunol Res2013-08-01T00:00:002013Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.24829746Geynisman DM, Zha Y, Kunnavakkam R, Aklilu M, Catenacci DV, Polite BN, Rosenbaum C, Namakydoust A, Karrison T, Gajewski TF, Kindler HLJournal for immunotherapy of cancerA randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma. J Immunother Cancer. 2013; 1:8.J Immunother Cancer2013-06-27T00:00:002013A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma.24983965Catenacci DV, Liao WL, Thyparambil S, Henderson L, Xu P, Zhao L, Rambo B, Hart J, Xiao SY, Bengali K, Uzzell J, Darfler M, Krizman DB, Cecchi F, Bottaro DP, Karrison T, Veenstra TD, Hembrough T, Burrows JPloS oneAbsolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. PLoS One. 2014; 9(7):e100586.PLoS One2014-07-01T00:00:002014Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue.Authorship 84353326199386O'Donnell PH, Karovic S, Karrison TG, Janisch L, Levine MR, Harris PJ, Polite BN, Cohen EE, Fleming GF, Ratain MJ, Maitland MLClinical cancer research : an official journal of the American Association for Cancer ResearchSerum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res. 2015 Nov 15; 21(22):5092-9.Clin Cancer Res2015-07-21T00:00:002015Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.Authorship 8465014Authorship 847031726405147Hutson SL, Wheeler KM, McLone D, Frim D, Penn R, Swisher CN, Heydemann PT, Boyer KM, Noble AG, Rabiah P, Withers S, Montoya JG, Wroblewski K, Karrison T, Grigg ME, McLeod RClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaPatterns of Hydrocephalus Caused by Congenital Toxoplasma gondii Infection Associate With Parasite Genetics. Clin Infect Dis. 2015 Dec 15; 61(12):1831-4.Clin Infect Dis2015-09-24T00:00:002015Patterns of Hydrocephalus Caused by Congenital Toxoplasma gondii Infection Associate With Parasite Genetics.26405150Contopoulos-Ioannidis D, Wheeler KM, Ramirez R, Press C, Mui E, Zhou Y, Van Tubbergen C, Prasad S, Maldonado Y, Withers S, Boyer KM, Noble AG, Rabiah P, Swisher CN, Heydemann P, Wroblewski K, Karrison T, Grigg ME, Montoya JG, McLeod RClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaClustering of Toxoplasma gondii Infections Within Families of Congenitally Infected Infants. Clin Infect Dis. 2015 Dec 15; 61(12):1815-24.Clin Infect Dis2015-09-24T00:00:002015Clustering of Toxoplasma gondii Infections Within Families of Congenitally Infected Infants.Authorship 84992326527777Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz HJ, Stiff P, Kumar P, Xu P, Henderson L, Takebe N, Salgia R, Wang X, Stadler WM, de Sauvage FJ, Kindler HLJournal of clinical oncology : official journal of the American Society of Clinical OncologyRandomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Dec 20; 33(36):4284-92.J Clin Oncol2015-11-02T00:00:002015Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.Chicago60637ILAuthorship 857303Authorship 85573626486998Yao K, Liederbach E, Lutfi W, Wang CH, Hou N, Karrison T, Huo DJournal of surgical oncologyIncreased utilization of postmastectomy radiotherapy in the United States from 2003 to 2011 in patients with one to three tumor positive nodes. J Surg Oncol. 2015 Dec; 112(8):809-14.J Surg Oncol2015-10-20T00:00:002015Increased utilization of postmastectomy radiotherapy in the United States from 2003 to 2011 in patients with one to three tumor positive nodes.26493492Posadas EM, Ahmed RS, Karrison T, Szmulewitz RZ, O'Donnell PH, Wade JL, Shen J, Gururajan M, Sievert M, Stadler WMThe ProstateSaracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. Prostate. 2016 Feb 15; 76(3):286-93.Prostate2015-10-23T00:00:002015Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.Authorship 87525226598548Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, Roberts JD, Vokes EE, Cohen EEAnnals of oncology : official journal of the European Society for Medical OncologyPhase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016 Feb; 27(2):318-23.Ann Oncol2015-11-23T00:00:002015Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.Authorship 89177326884588Villaflor VM, Melotek JM, Karrison TG, Brisson RJ, Blair EA, Portugal L, De Souza JA, Ginat DT, Stenson KM, Langerman A, Kocherginsky M, Spiotto MT, Hannigan N, Seiwert TY, Cohen EE, Vokes EE, Haraf DJAnnals of oncology : official journal of the European Society for Medical OncologyResponse-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. Ann Oncol. 2016 05; 27(5):908-13.Ann Oncol2016-02-15T00:00:002016Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer.Authorship 90289626944478Stoddart A, Qian Z, Fernald AA, Bergerson RJ, Wang J, Karrison T, Anastasi J, Bartom ET, Sarver AL, McNerney ME, Largaespada DA, Le Beau MMHaematologicaRetroviral insertional mutagenesis identifies the del(5q) genes, CXXC5, TIFAB and ETF1, as well as the Wnt pathway, as potential targets in del(5q) myeloid neoplasms. Haematologica. 2016 06; 101(6):e232-6.Haematologica2016-03-04T00:00:002016Retroviral insertional mutagenesis identifies the del(5q) genes, CXXC5, TIFAB and ETF1, as well as the Wnt pathway, as potential targets in del(5q) myeloid neoplasms.Authorship 90486727044931Choudhury NJ, Campanile A, Antic T, Yap KL, Fitzpatrick CA, Wade JL, Karrison T, Stadler WM, Nakamura Y, O'Donnell PHJournal of clinical oncology : official journal of the American Society of Clinical OncologyAfatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations. J Clin Oncol. 2016 06 20; 34(18):2165-71.J Clin Oncol2016-04-04T00:00:002016Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.Authorship 91041326860793Pearce SM, Pariser JJ, Karrison T, Patel SG, Eggener SEThe Journal of urologyComparison of Perioperative and Early Oncologic Outcomes between Open and Robotic Assisted Laparoscopic Prostatectomy in a Contemporary Population Based Cohort. J Urol. 2016 07; 196(1):76-81.J Urol2016-02-06T00:00:002016Comparison of Perioperative and Early Oncologic Outcomes between Open and Robotic Assisted Laparoscopic Prostatectomy in a Contemporary Population Based Cohort.Authorship 502613Authorship 502243Authorship 504612Authorship 505993Authorship 507382Authorship 508013Authorship 507102Authorship 509632Authorship 512602Authorship 501782Authorship 505223Authorship 512943Authorship 518822Authorship 503217Authorship 510789Authorship 510824Authorship 511173Authorship 506909Authorship 519563Authorship 511846Authorship 519625Authorship 521444Authorship 523632Authorship 533731Authorship 511934Authorship 517894Authorship 506964Authorship 507622Authorship 536417Authorship 536948Authorship 513623Authorship 528793Authorship 537504Authorship 539522Authorship 511825Authorship 513233Authorship 513563Authorship 511584Authorship 511807Authorship 518112Authorship 540975Authorship 542943Authorship 544145Authorship 512902Authorship 522743Authorship 525923Authorship 526023Authorship 550964Authorship 552785Authorship 517243Authorship 519243Authorship 519951Authorship 525262Authorship 5617720Authorship 526871Authorship 568984Authorship 529763Authorship 529553Authorship 529691Authorship 569395Authorship 535471Authorship 536225Authorship 541224Authorship 523622Authorship 530845Authorship 578804Authorship 527621Authorship 545083Authorship 546007Authorship 582636Authorship 535723Authorship 535983Authorship 547294Authorship 531912Authorship 532062Authorship 538905Authorship 539758Authorship 5404711Authorship 533704Authorship 551702Authorship 536872Authorship 529032Authorship 531143Authorship 532023Authorship 532072Authorship 552867Authorship 553273Authorship 539064Authorship 562573Authorship 540023Authorship 542443Authorship 542625Authorship 544602Authorship 543721Authorship 544961Authorship 533061Authorship 550566Authorship 550576Authorship 554702Authorship 556016Authorship 5917114Authorship 5920423Authorship 557736Authorship 557096Authorship 560144Authorship 535812Authorship 557725Authorship 596293Authorship 597032Authorship 553554Authorship 599672Authorship 564713Authorship 553837Authorship 570413Authorship 570831Authorship 605963Authorship 573234Authorship 573332Authorship 544652Authorship 576143Authorship 576506Authorship 566772Authorship 567075Authorship 567552Authorship 568616Authorship 575618Authorship 550501Authorship 572656Authorship 573143Authorship 583922Authorship 578643Authorship 555216Authorship 582373Authorship 581547Authorship 579175Authorship 579963Authorship 5903313Authorship 587933Authorship 572267Authorship 593933Authorship 594935Authorship 597827Authorship 595567Authorship 596325Authorship 598416Authorship 611901Authorship 580266Authorship 580896Authorship 582173Authorship 609213Authorship 611498Authorship 6283212Authorship 620292Authorship 616657Authorship 513195Authorship 517625Authorship 520634Authorship 520693Authorship 531262Authorship 535512Authorship 536625Authorship 538419Authorship 546573Authorship 549218Authorship 554254Authorship 560588Authorship 563193Authorship 563993Authorship 564484Authorship 581985Authorship 5844415Authorship 585484Authorship 585604Authorship 585674Authorship 5948322402041Wolfe WH, Michalek JE, Miner JC, Rahe A, Silva J, Thomas WF, Grubbs WD, Lustik MB, Karrison TG, Roegner RHJAMAHealth status of Air Force veterans occupationally exposed to herbicides in Vietnam. I. Physical health. JAMA. 1990 Oct 10; 264(14):1824-31.JAMA1990-10-10T00:00:001990Health status of Air Force veterans occupationally exposed to herbicides in Vietnam. I. Physical health.2642730Meier P, Ferguson DJ, Karrison TCancerA controlled trial of extended radical versus radical mastectomy. Ten-year results. Cancer. 1989 Jan 01; 63(1):188-95.Cancer1989-01-01T00:00:001989A controlled trial of extended radical versus radical mastectomy. Ten-year results.4076549Kordylewski L, Goings G, Karrison T, Page EDevelopmental biologyDevelopmental changes in internal structure of chick heart plasma membrane. Dev Biol. 1985 Dec; 112(2):485-8.Dev Biol1985-12-01T00:00:001985Developmental changes in internal structure of chick heart plasma membrane.4064054Rochman H, Selhub J, Karrison TCancer detection and preventionFolate binding protein and the estrogen receptor in breast cancer. Cancer Detect Prev. 1985; 8(1-2):71-5.Cancer Detect Prev1985-01-01T00:00:001985Folate binding protein and the estrogen receptor in breast cancer.6290024Dawson PJ, Ferguson DJ, Karrison TCancerThe pathological findings of breast cancer in patients surviving 25 years after radical mastectomy. Cancer. 1982 Nov 15; 50(10):2131-8.Cancer1982-11-15T00:00:001982The pathological findings of breast cancer in patients surviving 25 years after radical mastectomy.6487059Cohen L, Morgan J, Babbs R, Karrison TG, Giacomoni MArchives of physical medicine and rehabilitationFast walking velocity in health and Duchenne muscular dystrophy: a statistical analysis. Arch Phys Med Rehabil. 1984 Oct; 65(10):573-8.Arch Phys Med Rehabil1984-10-01T00:00:001984Fast walking velocity in health and Duchenne muscular dystrophy: a statistical analysis.3956211Alamercery Y, Wilkins P, Karrison TControlled clinical trialsFunctional equality of coordinating centers in a multicenter clinical trial. Experience of the International Mexiletine and Placebo Antiarrhythmic Coronary Trial (IMPACT). Control Clin Trials. 1986 Mar; 7(1):38-52.Control Clin Trials1986-03-01T00:00:001986Functional equality of coordinating centers in a multicenter clinical trial. Experience of the International Mexiletine and Placebo Antiarrhythmic Coronary Trial (IMPACT).7122997Cohen L, Morgan J, Babbs R, Gilula Z, Karrison T, Meier PResearch communications in chemical pathology and pharmacologyA statistical analysis of the loss of muscle strength in Duchenne's muscular dystrophy. Res Commun Chem Pathol Pharmacol. 1982 Jul; 37(1):123-38.Res Commun Chem Pathol Pharmacol1982-07-01T00:00:001982A statistical analysis of the loss of muscle strength in Duchenne's muscular dystrophy.7261636Karrison TControlled clinical trialsData editing in a clinical trial. Control Clin Trials. 1981 May; 2(1):15-29.Control Clin Trials1981-05-01T00:00:001981Data editing in a clinical trial.6837754Page E, Karrison T, Upshaw-Earley JThe American journal of physiologyFreeze-fractured cardiac gap junctions: structural analysis by three methods. Am J Physiol. 1983 Apr; 244(4):H525-39.Am J Physiol1983-04-01T00:00:001983Freeze-fractured cardiac gap junctions: structural analysis by three methods.7837966Albert DA, Harel L, Karrison TMedicineThe treatment of rheumatic carditis: a review and meta-analysis. Medicine (Baltimore). 1995 Jan; 74(1):1-12.Medicine (Baltimore)1995-01-01T00:00:001995The treatment of rheumatic carditis: a review and meta-analysis.8030722Brown L, Karrison T, Cibils LAAmerican journal of obstetrics and gynecologyMode of delivery and perinatal results in breech presentation. Am J Obstet Gynecol. 1994 Jul; 171(1):28-34.Am J Obstet Gynecol1994-07-01T00:00:001994Mode of delivery and perinatal results in breech presentation.3872080Kordylewski L, Karrison T, Page EThe American journal of physiologyMeasurements on the internal structure of freeze-fractured cardiac plasma membrane. Am J Physiol. 1985 Mar; 248(3 Pt 2):H297-304.Am J Physiol1985-03-01T00:00:001985Measurements on the internal structure of freeze-fractured cardiac plasma membrane.3548942McGurrin JF, Doria MI, Dawson PJ, Karrison T, Stein HO, Franklin WACancerAssessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast. Cancer. 1987 May 15; 59(10):1744-50.Cancer1987-05-15T00:00:001987Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast.6606986Kordylewski L, Karrison T, Page EThe American journal of physiologyP-face particle density of freeze-fractured vertebrate cardiac plasma membrane. Am J Physiol. 1983 Dec; 245(6):H992-7.Am J Physiol1983-12-01T00:00:001983P-face particle density of freeze-fractured vertebrate cardiac plasma membrane.7109156Ferguson DJ, Meier P, Karrison T, Dawson PJ, Straus FH, Lowenstein FEJAMAStaging of breast cancer and survival rates. An assessment based on 50 years of experience with radical mastectomy. JAMA. 1982 Sep 17; 248(11):1337-41.JAMA1982-09-17T00:00:001982Staging of breast cancer and survival rates. An assessment based on 50 years of experience with radical mastectomy.9564817Sarpong SB, Karrison TThe Journal of allergy and clinical immunologySeason of birth and cockroach allergen sensitization in children with asthma. J Allergy Clin Immunol. 1998 Apr; 101(4 Pt 1):566-8.J Allergy Clin Immunol1998-04-01T00:00:001998Season of birth and cockroach allergen sensitization in children with asthma.8030730Cibils LA, Karrison T, Brown LAmerican journal of obstetrics and gynecologyFactors influencing neonatal outcomes in the very-low-birth-weight fetus (< 1500 grams) with a breech presentation. Am J Obstet Gynecol. 1994 Jul; 171(1):35-42.Am J Obstet Gynecol1994-07-01T00:00:001994Factors influencing neonatal outcomes in the very-low-birth-weight fetus (< 1500 grams) with a breech presentation.10430267Karrison TG, Vogelzang NJCancerIntrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study. Cancer. 1999 Aug 01; 86(3):546-7.Cancer1999-08-01T00:00:001999Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study.10498502Heimann R, Karrison T, Hellman SThe New England journal of medicineTreatment of ductal carcinoma in situ. N Engl J Med. 1999 Sep 23; 341(13):999-1000.N Engl J Med1999-09-23T00:00:001999Treatment of ductal carcinoma in situ.8333442Ober C, Karrison T, Harlow L, Elias S, Gleicher NAmerican journal of obstetrics and gynecologyAutoantibodies and pregnancy history in a healthy population. Am J Obstet Gynecol. 1993 Jul; 169(1):143-7.Am J Obstet Gynecol1993-07-01T00:00:001993Autoantibodies and pregnancy history in a healthy population.9396981Sarpong SB, Karrison TAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & ImmunologySensitization to indoor allergens and the risk for asthma hospitalization in children. Ann Allergy Asthma Immunol. 1997 Nov; 79(5):455-9.Ann Allergy Asthma Immunol1997-11-01T00:00:001997Sensitization to indoor allergens and the risk for asthma hospitalization in children.11794606Weir B, Disney L, Karrison TJournal of neurosurgerySizes of ruptured and unruptured aneurysms in relation to their sites and the ages of patients. J Neurosurg. 2002 Jan; 96(1):64-70.J Neurosurg2002-01-01T00:00:002002Sizes of ruptured and unruptured aneurysms in relation to their sites and the ages of patients.9890174Karrison TG, Ferguson DJ, Meier PJournal of the National Cancer InstituteDormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst. 1999 Jan 06; 91(1):80-5.J Natl Cancer Inst1999-01-06T00:00:001999Dormancy of mammary carcinoma after mastectomy.9129859Karrison TGControlled clinical trialsUse of Irwin's restricted mean as an index for comparing survival in different treatment groups--interpretation and power considerations. Control Clin Trials. 1997 Apr; 18(2):151-67.Control Clin Trials1997-04-01T00:00:001997Use of Irwin's restricted mean as an index for comparing survival in different treatment groups--interpretation and power considerations.8614753Karrison TStatistics in medicineConfidence intervals for median survival times under a piecewise exponential model with proportional hazards covariate effects. Stat Med. 1996 Jan 30; 15(2):171-82.Stat Med1996-01-30T00:00:001996Confidence intervals for median survival times under a piecewise exponential model with proportional hazards covariate effects.11155434Castaneda S, Karrison T, Cibils LAJournal of perinatal medicinePeripartum hysterectomy. J Perinat Med. 2000; 28(6):472-81.J Perinat Med2000-01-01T00:00:002000Peripartum hysterectomy.11408854Hibbard JU, Ismail MA, Wang Y, Te C, Karrison T, Ismail MAAmerican journal of obstetrics and gynecologyFailed vaginal birth after a cesarean section: how risky is it? I. Maternal morbidity. Am J Obstet Gynecol. 2001 Jun; 184(7):1365-71; discussion 1371-3.Am J Obstet Gynecol2001-06-01T00:00:002001Failed vaginal birth after a cesarean section: how risky is it? I. Maternal morbidity.8440504Zweibel NR, Cassel CK, Karrison TThe GerontologistPublic attitudes about the use of chronological age as a criterion for allocating health care resources. Gerontologist. 1993 Feb; 33(1):74-80.Gerontologist1993-02-01T00:00:001993Public attitudes about the use of chronological age as a criterion for allocating health care resources.8746887Karrison TStatistics in medicineComparison of median survival times with adjustment for covariates. Stat Med. 1995 Dec 15; 14(23):2537-53.Stat Med1995-12-15T00:00:001995Comparison of median survival times with adjustment for covariates.16188248Kaplan M, Herschel M, Hammerman C, Karrison T, Hoyer JD, Stevenson DKClinica chimica acta; international journal of clinical chemistryStudies in hemolysis in glucose-6-phosphate dehydrogenase-deficient African American neonates. Clin Chim Acta. 2006 Mar; 365(1-2):177-82.Clin Chim Acta2005-09-26T00:00:002005Studies in hemolysis in glucose-6-phosphate dehydrogenase-deficient African American neonates.11083601Buxton OM, Copinschi G, Van Onderbergen A, Karrison TG, Van Cauter ESleepA benzodiazepine hypnotic facilitates adaptation of circadian rhythms and sleep-wake homeostasis to an eight hour delay shift simulating westward jet lag. Sleep. 2000 Nov 01; 23(7):915-27.Sleep2000-11-01T00:00:002000A benzodiazepine hypnotic facilitates adaptation of circadian rhythms and sleep-wake homeostasis to an eight hour delay shift simulating westward jet lag.10580623Shimandle RB, Johnson D, Baker M, Stotland N, Karrison T, Arnow PMInfection control and hospital epidemiologySafety of peripheral intravenous catheters in children. Infect Control Hosp Epidemiol. 1999 Nov; 20(11):736-40.Infect Control Hosp Epidemiol1999-11-01T00:00:001999Safety of peripheral intravenous catheters in children.20837940Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, Smith S, Stiff P, Lester E, Modi S, Doyle LA, Vokes EE, Pro BJournal of clinical oncology : official journal of the American Society of Clinical OncologyTemsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 2010 Nov 01; 28(31):4740-6.J Clin Oncol2010-09-13T00:00:002010Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.9741864Karrison TG, Ober CControlled clinical trialsRecurrent miscarriage (REMIS) study: how should data from women who do not become pregnant be handled? Control Clin Trials. 1998 Oct; 19(5):430-9.Control Clin Trials1998-10-01T00:00:001998Recurrent miscarriage (REMIS) study: how should data from women who do not become pregnant be handled?12959428Weir B, Amidei C, Kongable G, Findlay JM, Kassell NF, Kelly J, Dai L, Karrison TGJournal of neurosurgeryThe aspect ratio (dome/neck) of ruptured and unruptured aneurysms. J Neurosurg. 2003 Sep; 99(3):447-51.J Neurosurg2003-09-01T00:00:002003The aspect ratio (dome/neck) of ruptured and unruptured aneurysms.9111492Sarpong SB, Wood RA, Karrison T, Eggleston PAThe Journal of allergy and clinical immunologyCockroach allergen (Bla g 1) in school dust. J Allergy Clin Immunol. 1997 Apr; 99(4):486-92.J Allergy Clin Immunol1997-04-01T00:00:001997Cockroach allergen (Bla g 1) in school dust.9564978Sarpong SB, Karrison TAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & ImmunologySkin test reactivity to indoor allergens as a marker of asthma severity in children with asthma. Ann Allergy Asthma Immunol. 1998 Apr; 80(4):303-8.Ann Allergy Asthma Immunol1998-04-01T00:00:001998Skin test reactivity to indoor allergens as a marker of asthma severity in children with asthma.11719594Aldrich CL, Stephenson MD, Karrison T, Odem RR, Branch DW, Scott JR, Schreiber JR, Ober CMolecular human reproductionHLA-G genotypes and pregnancy outcome in couples with unexplained recurrent miscarriage. Mol Hum Reprod. 2001 Dec; 7(12):1167-72.Mol Hum Reprod2001-12-01T00:00:002001HLA-G genotypes and pregnancy outcome in couples with unexplained recurrent miscarriage.19384693Kocherginsky M, Cohen EE, Karrison TJournal of biopharmaceutical statisticsDesign of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents. J Biopharm Stat. 2009; 19(3):524-9.J Biopharm Stat2009-01-01T00:00:002009Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents.23553850Sharma MR, Karrison TG, Kell B, Wu K, Turcich M, Geary D, Kang SP, Takebe N, Graham RA, Maitland ML, Schilsky RL, Ratain MJ, Cohen EEClinical cancer research : an official journal of the American Association for Cancer ResearchEvaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67.Clin Cancer Res2013-04-03T00:00:002013Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.23151808Gangadhar TC, Clark JI, Karrison T, Gajewski TFInvestigational new drugsPhase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs. 2013 Jun; 31(3):769-73.Invest New Drugs2012-11-15T00:00:002012Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.23844053Ferguson BD, Liu R, Rolle CE, Tan YH, Krasnoperov V, Kanteti R, Tretiakova MS, Cervantes GM, Hasina R, Hseu RD, Iafrate AJ, Karrison T, Ferguson MK, Husain AN, Faoro L, Vokes EE, Gill PS, Salgia RPloS oneThe EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. PLoS One. 2013; 8(7):e67668.PLoS One2013-07-02T00:00:002013The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.23251009Vokes EE, Salgia R, Karrison TGAnnals of oncology : official journal of the European Society for Medical OncologyEvidence-based role of bevacizumab in non-small cell lung cancer. Ann Oncol. 2013 Jan; 24(1):6-9.Ann Oncol2013-01-01T00:00:002013Evidence-based role of bevacizumab in non-small cell lung cancer.23310949Churpek JE, Pro B, van Besien K, Kline J, Conner K, Wade JL, Hagemeister F, Karrison T, Smith SMCancerA phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas. Cancer. 2013 May 01; 119(9):1683-9.Cancer2013-01-10T00:00:002013A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas.19717471Jiang Y, Lucas I, Young DJ, Davis EM, Karrison T, Rest JS, Le Beau MMHuman molecular geneticsCommon fragile sites are characterized by histone hypoacetylation. Hum Mol Genet. 2009 Dec 01; 18(23):4501-12.Hum Mol Genet2009-08-28T00:00:002009Common fragile sites are characterized by histone hypoacetylation.23443753Maitland ML, Wu K, Sharma MR, Jin Y, Kang SP, Stadler WM, Karrison TG, Ratain MJ, Bies RRClinical pharmacology and therapeuticsEstimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther. 2013 Apr; 93(4):345-51.Clin Pharmacol Ther2012-12-27T00:00:002012Estimation of renal cell carcinoma treatment effects from disease progression modeling.2411152Doyle DD, Brill DM, Wasserstrom JA, Karrison T, Page EThe American journal of physiologySaxitoxin binding and "fast" sodium channel inhibition in sheep heart plasma membrane. Am J Physiol. 1985 Aug; 249(2 Pt 2):H328-36.Am J Physiol1985-08-01T00:00:001985Saxitoxin binding and "fast" sodium channel inhibition in sheep heart plasma membrane.3019865Dawson PJ, Karrison T, Ferguson DJHuman pathologyHistologic features associated with long-term survival in breast cancer. Hum Pathol. 1986 Oct; 17(10):1015-21.Hum Pathol1986-10-01T00:00:001986Histologic features associated with long-term survival in breast cancer.3775759Kordylewski L, Karrison T, Page ETissue & cellDevelopmental changes in P-face and E-face particle densities of Xenopus cardiac muscle plasma membrane. Tissue Cell. 1986; 18(5):793-801.Tissue Cell1986-01-01T00:00:001986Developmental changes in P-face and E-face particle densities of Xenopus cardiac muscle plasma membrane.3881160Meier P, Ferguson DJ, Karrison TCancerA controlled trial of extended radical mastectomy. Cancer. 1985 Feb 15; 55(4):880-91.Cancer1985-02-15T00:00:001985A controlled trial of extended radical mastectomy.3948372Rajfer SI, Rossen JD, Douglas FL, Goldberg LI, Karrison TCirculationEffects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels. Circulation. 1986 Apr; 73(4):740-8.Circulation1986-04-01T00:00:001986Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels.9018288Woods K, Karrison T, Koshy M, Patel A, Friedmann P, Cassel CPublic health reports (Washington, D.C. : 1974)Hospital utilization patterns and costs for adult sickle cell patients in Illinois. Public Health Rep. 1997 Jan-Feb; 112(1):44-51.Public Health Rep1997-01-01T00:00:001997Hospital utilization patterns and costs for adult sickle cell patients in Illinois.17163577Chappell R, Karrison TStatistics in medicineContinuous Bayesian adaptive randomization based on event times with covariates by Cheung et al., Statistics in Medicine 2006; 25:55-70. Stat Med. 2007 Jul 10; 26(15):3050-2; author reply 3052-4.Stat Med2007-07-10T00:00:002007Continuous Bayesian adaptive randomization based on event times with covariates by Cheung et al., Statistics in Medicine 2006; 25:55-70.19443477Casalino LP, Nicholson S, Gans DN, Hammons T, Morra D, Karrison T, Levinson WHealth affairs (Project Hope)What does it cost physician practices to interact with health insurance plans? Health Aff (Millwood). 2009 Jul-Aug; 28(4):w533-43.Health Aff (Millwood)2009-05-14T00:00:002009What does it cost physician practices to interact with health insurance plans?23319693Karrison TGJournal of clinical oncology : official journal of the American Society of Clinical OncologyEstimation of progression-free survival in the randomized discontinuation trial design. J Clin Oncol. 2013 Feb 20; 31(6):814.J Clin Oncol2013-01-14T00:00:002013Estimation of progression-free survival in the randomized discontinuation trial design.Authorship 953991Authorship 9534711Authorship 958679Authorship 96035927634566Sweis RF, Medved M, Towey S, Karczmar GS, Oto A, Szmulewitz RZ, O'Donnell PH, Fishkin P, Karrison T, Stadler WMClinical genitourinary cancerDynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212.Clin Genitourin Cancer2016-08-17T00:00:002016Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma.22577474Noble AG, Latkany P, Kusmierczyk J, Mets M, Rabiah P, Boyer K, Jalbrzikowski J, Wroblewski K, Karrison T, Swisher CN, Mieler WF, Meier P, McLeod R, the Toxoplasmosis Study GroupScientia medicaChorioretinal lesions in mothers of children with congenital toxoplasmosis in the National Collaborative Chicago-based, Congenital Toxoplasmosis Study. Sci Med (Porto Alegre). 2010; 20(1):20-26.Sci Med (Porto Alegre)2010-01-01T00:00:002010Chorioretinal lesions in mothers of children with congenital toxoplasmosis in the National Collaborative Chicago-based, Congenital Toxoplasmosis Study.27214075Marino SR, Lee SM, Binkowski TA, Wang T, Haagenson M, Wang HL, Maiers M, Spellman S, van Besien K, Lee SJ, Karrison T, Artz ABone marrow transplantationIdentification of high-risk amino-acid substitutions in hematopoietic cell transplantation: a challenging task. Bone Marrow Transplant. 2016 Oct; 51(10):1342-1349.Bone Marrow Transplant2016-05-23T00:00:002016Identification of high-risk amino-acid substitutions in hematopoietic cell transplantation: a challenging task.Authorship 968071027839852Olopade CO, Frank E, Bartlett E, Alexander D, Dutta A, Ibigbami T, Adu D, Olamijulo J, Arinola G, Karrison T, Ojengbede OEnvironment internationalEffect of a clean stove intervention on inflammatory biomarkers in pregnant women in Ibadan, Nigeria: A randomized controlled study. Environ Int. 2017 Jan; 98:181-190.Environ Int2016-11-10T00:00:002016Effect of a clean stove intervention on inflammatory biomarkers in pregnant women in Ibadan, Nigeria: A randomized controlled study.Authorship 97999727285764Saloura V, Vougiouklakis T, Zewde M, Kiyotani K, Park JH, Gao G, Karrison T, Lingen M, Nakamura Y, Hamamoto ROncotargetWHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck. Oncotarget. 2016 Jul 05; 7(27):42527-42538.Oncotarget2016-07-05T00:00:002016WHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck.Authorship 991802Authorship 992231028077434Arina A, Karrison T, Galka E, Schreiber K, Weichselbaum RR, Schreiber HCancer immunology researchTransfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication. Cancer Immunol Res. 2017 02; 5(2):127-136.Cancer Immunol Res2017-01-11T00:00:002017Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.28081369Alexander D, Northcross A, Wilson N, Dutta A, Pandya R, Ibigbami T, Adu D, Olamijulo J, Morhason-Bello O, Karrison T, Ojengbede O, Olopade COAmerican journal of respiratory and critical care medicineRandomized Controlled Ethanol Cookstove Intervention and Blood Pressure in Pregnant Nigerian Women. Am J Respir Crit Care Med. 2017 06 15; 195(12):1629-1639.Am J Respir Crit Care Med2017-06-15T00:00:002017Randomized Controlled Ethanol Cookstove Intervention and Blood Pressure in Pregnant Nigerian Women.